EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	2396	((562/465) or (562/471) or (514/683) or (546/339) or (514/277)).CCLS.	US-PGPUB; USPAT	OR	OFF	2006/11/27 11:17
L2	0	1 and phenylalkanoic and acid and phenyloxyalkanoic and acid	US-PGPUB; USPAT	OR	OFF	2006/11/27 11:17

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\ererol.str



chain nodes :
1 2 3 4 5 6 7 8 13 14 15 16 27 28 29 30 31 37 38 39 49
50 51 52 53 57
ring nodes :
20 21 22 23 24 25 41 42 43 44 45 46
chain bonds :
1-2 2-3 2-4 4-13 7-8 13-22 14-15 15-16 25-37 30-31 37-38 38-39
39-43 50-51 50-52 50-53
ring bonds :
20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43 43-44 44-45
45-46
exact/norm bonds :
4-13 13-22 25-37 37-38 38-39 39-43
exact bonds :
2-4 7-8 14-15 15-16 30-31 50-51 50-52 50-53
normalized bonds :
1-2 2-3 20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43
43-44 44-45 45-46
isolated ring systems :
containing 20 : 41 :

G1:[*1],[*2],[*3],[*4]

G2:[*5],[*6],[*7],[*8]

G3:X,[*9],[*10]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
37:CLASS 38:CLASS 39:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 57:CLASS
58:Atom

Generic attributes :
    39:
    Saturation : Unsaturated
    Number of Carbon Atoms : less than 7
    Type of Ring System : Monocyclic

Element Count :
    Node 39: Limited
        C,C5-6
        N,N0-1

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\dfdfkl.str



chain nodes :
1 2 3 4 5 6 7 8 13 14 15 16 27 28 29 30 31 37 38 39 49
50 51 52 53 57
ring nodes :
20 21 22 23 24 25 41 42 43 44 45 46
chain bonds :
1-2 2-3 2-4 4-13 7-8 13-22 14-15 15-16 24-37 30-31 37-38 38-39
39-43 50-51 50-52 50-53
ring bonds :
20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43 43-44 44-45
45-46
exact/norm bonds :
4-13 13-22 24-37 37-38 38-39 39-43
exact bonds :
2-4 7-8 14-15 15-16 30-31 50-51 50-52 50-53
normalized bonds :
1-2 2-3 20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43
43-44 44-45 45-46
isolated ring systems :
containing 20 : 41 :

G1:[*1],[*2],[*3],[*4]

G2:[*5],[*6],[*7],[*8]

G3:X,[*9],[*10]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
37:CLASS 38:CLASS 39:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 57:CLASS
58:Atom

Generic attributes :
    39:
    Saturation : Unsaturated
    Number of Carbon Atoms : less than 7
    Type of Ring System : Monocyclic

Element Count :
    Node 39: Limited
        C,C5-6
        N,N0-1

C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\aqkm.str



chain nodes :
1 2 3 4 5 6 7 8 13 14 15 16 27 28 29 30 31 37 38 39 49
50 51 52 53 57
ring nodes :
20 21 22 23 24 25 41 42 43 44 45 46
chain bonds :
1-2 2-3 2-4 4-13 7-8 13-22 14-15 15-16 23-37 30-31 37-38 38-39
39-43 50-51 50-52 50-53
ring bonds :
20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43 43-44 44-45
45-46
exact/norm bonds :
4-13 13-22 23-37 37-38 38-39 39-43
exact bonds :
2-4 7-8 14-15 15-16 30-31 50-51 50-52 50-53
normalized bonds :
1-2 2-3 20-21 20-25 21-22 22-23 23-24 24-25 41-42 41-46 42-43
43-44 44-45 45-46
isolated ring systems :
containing 20 : 41 :

G1:[*1],[*2],[*3],[*4]

G2:[*5],[*6],[*7],[*8]

G3:X,[*9],[*10]

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:Atom 21:Atom 22:Atom 23:Atom
24:Atom 25:Atom 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS
37:CLASS 38:CLASS 39:Atom 41:Atom 42:Atom 43:Atom 44:Atom 45:Atom
46:Atom 49:CLASS 50:CLASS 51:CLASS 52:CLASS 53:CLASS 57:CLASS
58:Atom

Generic attributes :
    39:
    Saturation : Unsaturated
    Number of Carbon Atoms : less than 7
    Type of Ring System : Monocyclic

Element Count :
    Node 39: Limited
        C,C5-6
        N,N0-1

10518679

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that

Updated Search

specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6
DICTIONARY FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\ererol.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 01:24:48 FILE 'REGISTRY'

Updated Search

10518679

SAMPLE SCREEN SEARCH COMPLETED - 44386 TO ITERATE

4.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 875143 TO 900297
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 01:24:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 888904 TO ITERATE

98.8% PROCESSED 878586 ITERATIONS 320 ANSWERS

100.0% PROCESSED 888904 ITERATIONS 403 ANSWERS
SEARCH TIME: 00.00.25

L3 403 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	173.10	173.31

FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907 - 27 Nov 2006 VOL 145 ISS 23
FILE LAST UPDATED: 26 Nov 2006 (20061126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4 20 L3

=> s l4 and stevenage, r?/au

Updated Search

10518679

```
            0 STEVENAGE, R?/AU
L5          0 L4 AND STEVENAGE, R?/AU

=> s l4 and beswick, p?/au
           57 BESWICK, P?/AU
L6          1 L4 AND BESWICK, P?/AU

=> d l6, ibib abs hitstr, 1

L6   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:2698  HCAPLUS
DOCUMENT NUMBER:          140:59519
TITLE:                    Preparation of (biphenylylalkoxy)- and
                          [(phenylpyridyl)alkoxy]-substituted phenylalkanoic
                          acids and phenoxyalkanoic acids as hPPAR activators
                          for treatment of cardiovascular disease and related
                          disorders
INVENTOR(S):              Hamlett, Christopher Charles Frederick; Bell, Richard;
                          Beswick, Paul John; Gosmini, Romain Luc Marie;
                          King, Nigel Paul; Patel, Vipulkumar Kantibhai
PATENT ASSIGNEE(S):       Smithkline Beecham Corporation, USA
SOURCE:                   PCT Int. Appl., 158 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000315	A1	20031231	WO 2003-EP6415	20030618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487909	AA	20031231	CA 2003-2487909	20030618
AU 2003245962	A1	20040106	AU 2003-245962	20030618
EP 1513526	A1	20050316	EP 2003-738056	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011931	A	20050405	BR 2003-11931	20030618
CN 1674897	A	20050928	CN 2003-819290	20030618
JP 2005534672	T2	20051117	JP 2004-514761	20030618
NZ 537210	A	20060929	NZ 2003-537210	20030618
NO 2004005328	A	20050309	NO 2004-5328	20041203
US 2006089394	A1	20060427	US 2005-518679	20050816
PRIORITY APPLN. INFO.:			GB 2002-14149 A	20020619
			WO 2003-EP6415 W	20030618

```
OTHER SOURCE(S):          MARPAT 140:59519
GI
```

Updated Search



I



II

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = O or (CH2)n; n = 0-2; R3 R4 = independently H, alkyl, OMe, CF3, allyl, or halo; X1 = O, S, SO2, SO, or CH2; R5 and R6 = independently H, (halo)alkyl, or alkoxyalkyl; or CR5R6 = cycloalkyl; R7 = (un)substituted Ph or 6-membered heteroaryl; and pharmaceutically acceptable salts, solvates, and hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, a mixture of 3-(bromomethyl)-4'-(trifluoromethyl)biphenyl, Et (4-mercapto-2-methylphenoxy)acetate, and polymer-supported diisopropylethylamine in DCM was stirred at room temperature overnight to give the thioether. Saponification of the ester with aqueous NaOH in THF and acidification afforded II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

IT 638215-22-2P, [[2-Methyl-4-[[[4'-(trifluoromethyl)biphenyl-3-yl]methyl]thio]phenyl]oxy]acetic acid 638215-23-3P, [[2-Methyl-4-[[[4-methyl-4'-(trifluoromethyl)biphenyl-3-yl]methyl]thio]phenyl]oxy]acetic acid 638215-24-4P, 3-[2-Methyl-4-[[[4'-(trifluoromethyl)biphenyl-3-yl]methyl]oxy]phenyl]propanoic acid 638215-25-5P, [[2-Methyl-4-[2-[4'-(trifluoromethyl)biphenyl-3-yl]ethyl]phenyl]oxy]acetic acid 638215-26-6P, [[2-Methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]phenyl]oxy]acetic acid 638215-27-7P, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-3-yl]ethyl]thio]phenyl]oxy]acetic acid 638215-28-8P, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-4-yl]ethyl]thio]phenyl]oxy]acetic acid 638215-29-9P, 2-Methyl-2-[[2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]propanoic acid 638215-30-2P, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-3-yl]pentyl]oxy]phenyl]oxy]acetic acid 638215-31-3P, [[4-[[1-(4'-Chlorobiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid

638215-32-4P, [[2-Methyl-4-[[1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]oxy]phenyl]oxy]acetic acid 638215-33-5P, [[4-[[1-(4'-Chlorobiphenyl-4-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-34-6P, [[2-Methyl-4-[[(1R)-1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]thio]phenyl]oxy]acetic acid 638215-35-7P, [[2-Methyl-4-[[(1S)-1-[4'-(trifluoromethyl)biphenyl-4-yl]pentyl]thio]phenyl]oxy]acetic acid 638215-36-8P, [[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-37-9P, [[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-38-0P, [[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenyl]oxy]acetic acid 638215-39-1P, [[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenyl]oxy]acetic acid 638215-40-4P, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfinyl]phenyl]oxy]acetic acid 638215-41-5P, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfonyl]phenyl]oxy]acetic acid 638215-43-7P, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butyl]oxy]phenyl]oxy]acetic acid 638215-45-9P, [[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-46-0P, 3-[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638215-47-1P, [[4-[[1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-50-6P, [[2-Methyl-4-[[1-[6-(4-methylphenyl)-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-51-7P, [[4-[[1-[6-(3,4-Dichlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-52-8P , [[2-Methyl-4-[[1-[6-[3-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-55-1P, [[4-[[1-[6-(4-Fluorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-57-3P, [[2-Methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]hexyl]oxy]phenyl]oxy]acetic acid 638215-58-4P, [[2-Methyl-4-[[4-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-59-5P, [[2-Methyl-4-[[3-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butyl]oxy]phenyl]oxy]acetic acid 638215-64-2P, [[4-[[1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenyl]oxy]acetic acid 638215-67-5P, [[2-Ethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]oxy]acetic acid 638215-68-6P, 4-[4-[[1-[6-[4-(Trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]butanoic acid 638215-69-7P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-74-4P , [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-79-9P, [[2-Methyl-4-[[(1R)-3-(methyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propyl]oxy]phenyl]oxy]acetic acid 638215-80-2P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-3-(methyloxy)propyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-81-3P, [[2-Methyl-4-[[(1S)-3-(methyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propyl]oxy]phenyl]oxy]acetic acid 638215-82-4P, [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-3-(methyloxy)propyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-83-5P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-87-9P, [[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-88-0P, [[4-[[(1S)-2-

(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-92-6P, [[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-93-7P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-94-8P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-96-0P, [[4-[[(1R)-1-[6-(4-Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-98-2P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638215-99-3P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-(4-fluorophenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-01-0P, [[4-[[(1R)-1-[6-(4-Chloro-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-02-1P, [[4-[[(1R)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-03-2P, [[4-[[(1R)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-04-3P, [[4-[[(1R)-2-(Ethyloxy)-1-[6-[3-fluoro-4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-05-4P, [[4-[[(1R)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-06-5P, [[4-[[(1R)-1-[6-(4-Cyano-2-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-07-6P, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-08-7P, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-10-1P, [[4-[[(1S)-1-[6-(4-Cyano-3-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-12-3P, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-13-4P, [[4-[[(1S)-2-(Ethyloxy)-1-[6-(4-fluorophenyl)-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-15-6P, [[4-[[(1S)-1-[6-(4-Chloro-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-16-7P, [[4-[[(1S)-1-[6-(3-Chloro-4-cyanophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-17-8P, [[4-[[(1S)-1-[6-(4-Cyano-3-methylphenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-18-9P, [[4-[[(1S)-2-(Ethyloxy)-1-[6-[3-fluoro-4-(methyloxy)phenyl]-2-pyridinyl]ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-19-0P, [[4-[[(1S)-1-[6-(4-Cyano-2-fluorophenyl)-2-pyridinyl]-2-(ethyloxy)ethyl]oxy]-2-methylphenyl]oxy]acetic acid 638216-21-4P, 3-[2-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-25-8P, 3-[4-[[(1S)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-26-9P, 3-[2-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-30-5P, 3-[4-[[(1R)-1-[6-(4-Chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenyl]propanoic acid 638216-31-6P, 3-[3,5-Dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-32-7P, 3-[3-(Methyloxy)-5-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-33-8P, 3-[3-Propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-34-9P, 3-[3-(Ethyloxy)-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-

Updated Search

pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-35-0P,
3-[4-[[(1R)-1-[6-[4-(Trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-36-1P,
3-[3-(Methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-40-7P,
3-[4-[[(1S)-1-[6-[4-(Trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-41-8P,
3-[3-(Methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-45-2P,
3-[3-Fluoro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-46-3P,
3-[3-Methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-47-4P,
3-[3,5-Bis(methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-48-5P,
3-[2-(Methyloxy)-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-49-6P,
3-[3-Fluoro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-50-9P,
3-[3-Methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-51-0P,
3-[3,5-Bis(methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-52-1P,
3-[2-(Methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-53-2P,
3-[3-Chloro-5-(methyloxy)-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-54-3P,
3-[3-Chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-55-4P,
3-[2-Chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-56-5P,
3-[3-Chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-57-6P,
3-[2-Chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]pentyl]oxy]phenyl]propanoic acid 638216-58-7P,
[[2-Methyl-4-[[1-[2-methyl-4'-(trifluoromethyl)biphenyl-3-
yl]pentyl]oxy]phenyl]oxy]acetic acid 638216-59-8P,
[[4-[[1-(4'-Chloro-2-methylbiphenyl-3-yl)pentyl]oxy]-2-
methylphenyl]oxy]acetic acid 638216-60-1P, [[4-[[1-(2,4'-
Dimethylbiphenyl-3-yl)pentyl]oxy]-2-methylphenyl]oxy]acetic acid
638216-63-4P, [[4-[[1-(4'-Fluoro-2-methylbiphenyl-3-yl)pentyl]oxy]-
2-methylphenyl]oxy]acetic acid 638216-64-5P,
[[2-Methyl-4-[[2-(propyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]ethyl]oxy]phenyl]oxy]acetic acid 638216-65-6P,
[[4-[[2-(Ethyloxy)-1-[6-[4-(trifluoromethyl)phenyl]-2-
pyridinyl]ethyl]thio]-2-methylphenyl]oxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(hPPAR activator; preparation of (aryloxy)phenylalkanoic acids and
(aryloxy)phenoxyalkanoic acids as hPPAR activators for treatment of
cardiovascular disease and related disorders)

RN 638215-22-2 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-
yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-23-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-24-4 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 638215-25-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-26-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 638215-27-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-28-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-29-9 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-30-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-3-

Updated Search

yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-31-3 HCAPLUS
CN Acetic acid, [4-[[1-(4'-chloro[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-32-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-33-5 HCAPLUS
CN Acetic acid, [4-[[1-(4'-chloro[1,1'-biphenyl]-4-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-34-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1R)-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-35-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-36-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-37-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-38-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-39-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-40-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfinyl]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 638215-41-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-43-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-45-9 HCAPLUS
CN Acetic acid, [4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 638215-46-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638215-47-1 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-50-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-(4-methylphenyl)-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 638215-51-7 HCAPLUS
CN Acetic acid, [4-[[1-[6-(3,4-dichlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-52-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[3-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-55-1 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-fluorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 638215-57-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]hexyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-58-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-59-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[3-methyl-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 638215-64-2 HCAPLUS
CN Acetic acid, [4-[[1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-ethylphenoxy]- (9CI) (CA INDEX NAME)



RN 638215-67-5 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-68-6 HCAPLUS
CN Benzenebutanoic acid, 4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638215-69-7 HCAPLUS
CN Acetic acid, [4-[[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-74-4 HCAPLUS
CN Acetic acid, [4-[[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-79-9 HCAPLUS
CN Acetic acid, [4-[(1R)-3-methoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-80-2 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]-3-methoxypropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-81-3 HCAPLUS
CN Acetic acid, [4-[(1S)-3-methoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]propoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-82-4 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]-3-methoxypropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-83-5 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-87-9 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-88-0 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-92-6 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-93-7 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-94-8 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-96-0 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638215-98-2 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638215-99-3 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-01-0 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-chloro-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-02-1 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-03-2 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-04-3 HCAPLUS
CN Acetic acid, [4-[(1R)-2-ethoxy-1-[6-(3-fluoro-4-methoxyphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-05-4 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-06-5 HCAPLUS
CN Acetic acid, [4-[(1R)-1-[6-(4-cyano-2-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-07-6 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(3-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-08-7 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-10-1 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-12-3 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(2-fluoro-4-methylphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-13-4 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(4-fluorophenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-15-6 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-chloro-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-16-7 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(3-chloro-4-cyanophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-17-8 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-3-methylphenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-18-9 HCAPLUS
CN Acetic acid, [4-[(1S)-2-ethoxy-1-[6-(3-fluoro-4-methoxyphenyl)-2-pyridinyl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-19-0 HCAPLUS
CN Acetic acid, [4-[(1S)-1-[6-(4-cyano-2-fluorophenyl)-2-pyridinyl]-2-ethoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-21-4 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-25-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-26-9 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-30-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-(4-chlorophenyl)-2-pyridinyl]pentyl]oxy]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-31-6 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-32-7 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-5-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-33-8 HCAPLUS

Updated Search

CN Benzenepropanoic acid, 3-propyl-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-34-9 HCAPLUS
CN Benzenepropanoic acid, 3-ethoxy-4-[[1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)



RN 638216-35-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 638216-36-1 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-40-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-41-8 HCAPLUS
CN Benzenepropanoic acid, 3-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-45-2 HCAPLUS
CN Benzenepropanoic acid, 3-fluoro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-46-3 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-47-4 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-48-5 HCAPLUS
CN Benzenepropanoic acid, 2-methoxy-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-49-6 HCAPLUS
CN Benzenepropanoic acid, 3-fluoro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-50-9 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-51-0 HCAPLUS
CN Benzenepropanoic acid, 3,5-dimethoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-52-1 HCAPLUS
CN Benzenepropanoic acid, 2-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-53-2 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-5-methoxy-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-54-3 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-55-4 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[[(1R)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-56-5 HCAPLUS
CN Benzenepropanoic acid, 3-chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 638216-57-6 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[[(1S)-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]pentyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 638216-58-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]pentyl]oxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 638216-59-8 HCAPLUS

Updated Search

CN Acetic acid, [4-[[1-(4'-chloro-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-60-1 HCAPLUS
CN Acetic acid, [4-[[1-(2,4'-dimethyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-63-4 HCAPLUS
CN Acetic acid, [4-[[1-(4'-fluoro-2-methyl[1,1'-biphenyl]-3-yl)pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 638216-64-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-propoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search





RN 638216-65-6 HCAPLUS
CN Acetic acid, [4-[[2-ethoxy-1-[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]ethyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 403 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4 20 S L3
L5 0 S L4 AND STEVENAGE, R?/AU
L6 1 S L4 AND BESWICK, P?/AU

=> s l4 not l6
L7 19 L4 NOT L6

=> s l7 and gosmini, r?/au

Updated Search

```
            17 GOSMINI, R?/AU
L8           0 L7 AND GOSMINI, R?/AU

=> s l7 and grimes, r?/au
           570 GRIMES, R?/AU
L9           0 L7 AND GRIMES, R?/AU

=> s l7 and hamlet, c?/au
            26 HAMLET, C?/AU
L10          0 L7 AND HAMLET, C?/AU

=> s l7 and hamlett, c?/au
             2 HAMLETT, C?/AU
L11          0 L7 AND HAMLETT, C?/AU

=> s l7 and king, n?/au
           596 KING, N?/AU
L12          0 L7 AND KING, N?/AU

=> s l7 and patel, v?/au
          1127 PATEL, V?/AU
L13          0 L7 AND PATEL, V?/AU

=> s l7 and bell, r?/au
          2752 BELL, R?/AU
L14          0 L7 AND BELL, R?/AU

=> d his

     (FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          403 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4           20 S L3
L5            0 S L4 AND STEVENAGE, R?/AU
L6            1 S L4 AND BESWICK, P?/AU
L7           19 S L4 NOT L6
L8            0 S L7 AND GOSMINI, R?/AU
L9            0 S L7 AND GRIMES, R?/AU
L10           0 S L7 AND HAMLET, C?/AU
L11           0 S L7 AND HAMLETT, C?/AU
L12           0 S L7 AND KING, N?/AU
L13           0 S L7 AND PATEL, V?/AU
L14           0 S L7 AND BELL, R?/AU

=> d l7, ibib abs hitstr, 1-19

L7   ANSWER 1 OF 19  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:398359  HCAPLUS
DOCUMENT NUMBER:          145:39840
TITLE:                    1,3,5-Trisubstituted aryls as highly selective
                          PPARδ agonists
AUTHOR(S):                Epple, Robert; Azimioara, Mihai; Russo, Ross;
                          Bursulaya, Badry; Tian, Shin-Shay; Gerken, Andrea;
                          Iskandar, Maya
```

Updated Search

10518679

CORPORATE SOURCE: Department of Medicinal Chemistry, Genomics Institute of the Novartis Research Foundation, San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(11), 2969-2973
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:39840

AB A series of highly potent and selective PPARδ agonists is described using the known non-selective ligand GW2433 as a structural template. Compound 1 is bioavailable, potent (10 nM), and shows no cross-activity with other PPAR subtypes up to 10 μM, making it a useful tool in studying the biol. effects of selective PPARδ activation.

IT 870289-06-8P 870289-09-1P 870289-15-9P
870289-38-6P 870289-39-7P 870289-41-1P
870289-44-4P 870289-56-8P 890137-40-3P
890137-41-4P 890137-43-6P 908831-17-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(1,3,5-Trisubstituted aryls as highly selective PPARδ agonists)

RN 870289-06-8 HCAPLUS
CN Acetic acid, [4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-09-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-(trifluoromethoxy)-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 870289-15-9 HCAPLUS
CN Acetic acid, [4-[[4-methoxy-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-38-6 HCAPLUS
CN Acetic acid, [4-[[3,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-39-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-(trifluoromethyl)[1,1':3',1'':4'',1'''-quaterphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 870289-41-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-methyl-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-44-4 HCAPLUS
CN Acetic acid, [4-[(4,4''-dichloro[1,1':3',1''-terphenyl]-5'-yl)methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 870289-56-8 HCAPLUS
CN Acetic acid, [4-[[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 890137-40-3 HCAPLUS
CN Acetic acid, [4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 890137-41-4 HCAPLUS
CN Propanoic acid, 2-[4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 890137-43-6 HCAPLUS
CN Acetic acid, [4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 908831-17-4 HCAPLUS
CN Acetic acid, [4-[[4,4''-bis(trifluoromethyl)[1,1':2',1''-terphenyl]-4'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:101282 HCAPLUS
DOCUMENT NUMBER: 144:184686
TITLE: Remedy for diabetes
INVENTOR(S): Suzuki, Nobuhiro; Suzuki, Masami; Asakawa, Tomoko; Kataoka, Osamu
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

Updated Search

10518679

WO 2006011615 A1 20060202 WO 2005-JP13995 20050726
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: JP 2004-218736 A 20040727
OTHER SOURCE(S): MARPAT 144:184686
GI



I

AB A remedy for diabetes with secondary sulfonylurea failure which contains a GPR40 agonist (I; Markush's structure given). Namely, a remedy for diabetes with secondary sulfonylurea failure capable of exerting excellent effects of secreting insulin and lowering the blood glucose level even on diabetic patients on whom sulfonylurea compds. or rapidly-acting insulin secretion promoters can exert no insulin secretion effect and thus a sufficient hypoglycemic effect cannot be established.

IT 691902-39-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(biphenylylmethoxybenzenepropanoate derivs. as GPR40 agonists and remedies for diabetes with secondary sulfonylurea failure)

RN 691902-39-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1262399 HCAPLUS
DOCUMENT NUMBER: 144:22712
TITLE: Triaryl compounds as PPAR modulators, their preparation, pharmaceutical compositions, and use in therapy

Updated Search

10518679

INVENTOR(S): Epple, Robert; Azimioara, Mihai
PATENT ASSIGNEE(S): Irm LLC, Bermuda
SOURCE: PCT Int. Appl., 59 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005113506	A1	20051201	WO 2005-US16747	20050513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-571004P P 20040514
OTHER SOURCE(S): MARPAT 144:22712
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to aryl compds. of formula I, which are modulators of peroxisome proliferator-activated receptors (PPAR), particularly PPARδ. In compds. I, m is 0-3; X, Y, and Z are independently selected from CH and N; L is (un)substituted (CH2)nO(CH2)n or (CH2)nS(O)p(CH2)n, where each n is independently selected from 0-4 and p is 0-2; R1 and R2 are independently selected from (un)substituted C3-12 cycloalkyl-A-, (un)substituted C3-8 heterocyclyl-A-, (un)substituted C6-10 aryl-A-, and (un)substituted C5-13 heteroaryl-A-, where A is a bond, C1-6 alkylene, C2-6 alkenylene, or C2-6 alkynylene; R3 is selected from halo, C1-6 alkyl, C1-6 alkoxy, C1-6 hydroxyalkyl, C1-6 haloalkyl, C1-6 haloalkoxy, (un)substituted C6-10 aryl, (un)substituted C5-10 heteroaryl, (un)substituted C3-12 cycloalkyl, and (un)substituted C3-8 heterocyclyl; and R4 is selected from (CH2)nO(CH2)nCO2R5 and (CH2)nCO2R5, where n is as defined previously and R5 is H or C1-6 alkyl; including pharmaceutically acceptable salts, hydrates, solvates, isomers, and prodrugs thereof. The invention also relates to the preparation of I, pharmaceutical compns. comprising a therapeutically effective amount of compound I in combination with one or more pharmaceutically acceptable excipients, as well as to the use of the compns. to treat or prevent diseases or disorders associated with PPAR activity. Substitution of Me bromoacetate with 4-hydroxy-3-methylacetophenone followed by Baeyer-Villiger oxidation and methanolysis gave phenoxyacetate II, which underwent substitution of 3,5-dibromobenzyl bromide to give dibromobenzyl ether III. Treatment of III with an excess of 4-trifluoromethylphenylboronic acid and ester hydrolysis resulted in the formation of terphenyl IV. Most preferred compds. of the invention express an EC50 value for PPARδ of less than 100 nM. The compds. of

Updated Search

the invention are at least 100-fold selective for PPARδ over PPARγ.

IT 870289-06-8P 870289-09-1P 870289-13-7P
870289-14-8P 870289-15-9P 870289-25-1P
870289-27-3P 870289-28-4P 870289-35-3P
870289-36-4P 870289-37-5P 870289-38-6P
870289-39-7P 870289-40-0P 870289-41-1P
870289-42-2P 870289-43-3P 870289-44-4P
870289-46-6P 870289-54-6P 870289-55-7P
870289-56-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of triaryl compds. as PPAR modulators and their use for treatment and prevention of diseases associated with PPARδ activity)

RN 870289-06-8 HCAPLUS
CN Acetic acid, [4-[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-09-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-(trifluoromethoxy)-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 870289-13-7 HCAPLUS
CN Acetic acid, [4-[[4''-methoxy-2-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-14-8 HCAPLUS
CN Acetic acid, [4-[[4''-methoxy-3-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-15-9 HCAPLUS
CN Acetic acid, [4-[[4-methoxy-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 870289-25-1 HCAPLUS
CN Acetic acid, [4-[[4''-methoxy-3,5-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-27-3 HCAPLUS
CN Acetic acid, [4-[(3,4-dichloro-4''-methoxy[1,1':3',1''-terphenyl]-5'-yl)methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-28-4 HCAPLUS
CN Acetic acid, [4-[(2-chloro-4''-methoxy[1,1':3',1''-terphenyl]-5'-yl)methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



RN 870289-35-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[3-(trifluoromethoxy)-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-36-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[5-(3-quinolinyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-37-5 HCAPLUS
CN Acetic acid, [4-[[2-methoxy-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 870289-38-6 HCAPLUS
CN Acetic acid, [4-[[3,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-39-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-(trifluoromethyl)[1,1':3',1'':4'',1'''-quaterphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-40-0 HCAPLUS
CN Acetic acid, [4-[[4-(dimethylamino)-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 870289-41-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-methyl-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-42-2 HCAPLUS
CN Acetic acid, [4-[[5-(6-methoxy-2-naphthalenyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-43-3 HCAPLUS
CN Acetic acid, [4-[[4-chloro-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 870289-44-4 HCAPLUS
CN Acetic acid, [4-[(4,4''-dichloro[1,1':3',1''-terphenyl]-5'-yl)methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 870289-46-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[5-(2-naphthalenyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-54-6 HCAPLUS

Updated Search

10518679

CN Acetic acid, [2-methyl-4-[[5-(4-pyridinyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-55-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[4-(methylthio)-4''-(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 870289-56-8 HCAPLUS
CN Acetic acid, [4-[[[4,4''-bis(trifluoromethyl)[1,1':3',1''-terphenyl]-5'-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:777848 HCAPLUS
DOCUMENT NUMBER: 145:262418
TITLE: A Critical Assessment of Docking Programs and Scoring Functions
AUTHOR(S): Warren, Gregory L.; Andrews, C. Webster; Capelli, Anna-Maria; Clarke, Brian; LaLonde, Judith; Lambert, Millard H.; Lindvall, Mika; Nevins, Neysa; Semus, Simon F.; Senger, Stefan; Tedesco, Giovanna; Wall, Ian D.; Woolven, James M.; Peishoff, Catherine E.; Head, Martha S.
CORPORATE SOURCE: GlaxoSmithKline Pharmaceuticals, Collegeville, PA, 19426, USA
SOURCE: Journal of Medicinal Chemistry (2006), 49(20), 5912-5931
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Docking is a computational technique that samples conformations of small mols. in protein binding sites; scoring functions are used to assess which of these conformations best complements the protein binding site. An evaluation of 10 docking programs and 37 scoring functions was conducted against eight proteins of seven protein types for three tasks: binding mode prediction, virtual screening for lead identification, and rank-ordering by affinity for lead optimization. All of the docking programs were able to generate ligand conformations similar to crystallog. determined protein/ligand complex structures for at least one of the targets. However, scoring functions were less successful at distinguishing the crystallog. conformation from the set of docked poses. Docking programs identified active compds. from a pharmaceutically relevant pool of decoy compds.; however, no single program performed well for all of the targets. For prediction of compound affinity, none of the docking programs or scoring functions made a useful prediction of ligand binding affinity.

IT 638215-26-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(critical assessment of docking programs and scoring functions)
RN 638215-26-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-

10518679

pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:612272 HCAPLUS
DOCUMENT NUMBER: 143:133168
TITLE: A preparation of 3-(4-benzyloxyphenyl)propanoic acid derivatives, useful as GPR40 receptor modulators
INVENTOR(S): Yasuma, Tsuneo; Kitamura, Shuji; Negoro, Nobuyuki
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063729	A1	20050714	WO 2004-JP19741	20041224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004309271	A1	20050714	AU 2004-309271	20041224
CA 2551610	AA	20050714	CA 2004-2551610	20041224
JP 2006083154	A2	20060330	JP 2004-373701	20041224
EP 1697339	A1	20060906	EP 2004-808091	20041224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				

PRIORITY APPLN. INFO.:
JP 2003-431629 A 20031225
JP 2004-241484 A 20040820
WO 2004-JP19741 W 20041224

OTHER SOURCE(S): MARPAT 143:133168
GI

Updated Search



I



II

AB The invention relates to a preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. of formula I [wherein: R1, R3, R4, and R5 are independently H, halogen, or hydrocarbon, etc.; R2 is halogen, NO2, NH2, or hydrocarbon, etc.; R6 and R7 are independently H, halogen, or alkoxy; R8 is H or (un)substituted amino-group; E is a bond, alkylene, or alkylene-O-alkylene, etc.; S is (un)substituted benzene] having a superior GPR40 receptor function modulating action, which can be used as an insulin secretagogue, an agent for the prophylaxis or treatment of diabetes. The invention compds. showed superior GPR40 receptor agonist activity, and also show superior properties as a pharmaceutical product, such as stability and the like. For instance, 3-(4-benzyloxyphenyl)propanoic acid derivative II (R9 = H; EC50 = 0.01 μM) was prepared via hydrolysis of ester II (R9 = Me) with a yield of 77%.

IT 858096-92-1P 858097-00-4P 858097-32-2P
858097-45-7P 858097-50-4P 858097-72-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. useful as GPR40 receptor modulators)

RN 858096-92-1 HCAPLUS

CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 858097-00-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-32-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-ethoxy-1-(ethoxymethyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-45-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(6-methyl-2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-50-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-72-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-4-hydroxy-1,1-dioxido-2H-thiopyran-4-yl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-

Updated Search

10518679

(9CI) (CA INDEX NAME)



IT 858096-72-7P 858096-74-9P 858096-76-1P
858096-78-3P 858096-80-7P 858096-82-9P
858096-84-1P 858096-86-3P 858096-88-5P
858096-90-9P 858096-95-4P 858096-97-6P
858097-01-5P 858097-03-7P 858097-05-9P
858097-07-1P 858097-09-3P 858097-11-7P
858097-14-0P 858097-16-2P 858097-18-4P
858097-20-8P 858097-22-0P 858097-25-3P
858097-26-4P 858097-35-5P 858097-36-6P
858097-37-7P 858097-38-8P 858097-39-9P
858097-40-2P 858097-42-4P 858097-47-9P
858097-49-1P 858097-51-5P 858097-52-6P
858097-53-7P 858097-55-9P 858097-58-2P
858097-60-6P 858097-62-8P 858097-64-0P
858097-67-3P 858097-69-5P 858097-74-2P
858097-76-4P 858097-78-6P 858097-80-0P
858097-82-2P 858097-83-3P 858097-86-6P
858097-89-9P 858097-91-3P 858097-92-4P
858097-94-6P 858097-98-0P 858097-99-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(4-benzyloxyphenyl)propanoic acid derivs. useful as GPR40 receptor modulators)

RN 858096-72-7 HCAPLUS

CN Benzenepropanoic acid, 4-[[2'-methyl-4'-[(tetrahydro-2H-pyran-2-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-74-9 HCAPLUS

CN Benzenepropanoic acid, 4-[(4'-hydroxy-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 858096-76-1 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-methoxy-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858096-78-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(cyclopropylmethoxy)-2'-methyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-80-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-(1-methylethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-82-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 858096-84-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-[2-(4-methyl-5-thiazolyl)ethoxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-86-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-[3-(2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-88-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-4'-(1-propylbutoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858096-90-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 858096-95-4 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[(4'-hydroxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858096-97-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(1-propylbutoxy)[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-01-5 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-hydroxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-03-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-chloro-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



RN 858097-05-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-fluoro-2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-07-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-09-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-11-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(cyclopropylmethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 858097-14-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(dimethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 858097-13-9
CMF C28 H33 N O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 858097-16-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',4'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-18-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',4',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 858097-20-8 HCAPLUS
CN Benzenepropanoic acid, 4-[(6-methoxy-2',4'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-22-0 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[(2',4',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-25-3 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[2'-[(4-fluorophenoxy)methyl]-4',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-26-4 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[4'-[(4-fluorophenoxy)methyl]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 858097-35-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(methoxymethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-36-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-ethoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-37-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-butoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-38-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[2-(phenylmethoxy)ethoxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)

Updated Search

PAGE 1-A



PAGE 1-B

— Ph

RN 858097-39-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-40-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(4'-butoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 858097-42-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(ethylthio)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-47-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-α,α-difluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 858097-49-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-51-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(6-methyl-2-pyridinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



RN 858097-52-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)

Updated Search

10518679



● HCl

RN 858097-53-7 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[2-(6-methyl-2-pyridinyl)ethoxy][1,1'-biphenyl]-3-yl]methoxy]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-55-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl-4'-nitro[1,1'-biphenyl]-3-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-58-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(ethylsulfonyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 858097-60-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(diethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-62-8 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[3-(2-oxo-1-pyrrolidinyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-64-0 HCAPLUS
CN Benzenepropanoic acid, 2-fluoro-4-[[4'-(methoxymethoxy)-2',6'-

Updated Search

dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 858097-67-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(acetylethylamino)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-69-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-74-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(methylsulfonyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 858097-76-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(3-thienylsulfonyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-78-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-(2-ethoxyethoxy)-6-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-80-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[3'-[[4-(2-carboxyethyl)-3-fluorophenoxy]methyl]-2,6-dimethyl[1,1'-biphenyl]-4-yl]oxy]methyl]-, 1-(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 858097-82-2 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-83-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(6-methyl-2-pyridinyl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 858097-86-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-1,1-dioxido-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)

Updated Search



RN 858097-89-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(3-methyl-3-oxetanyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-91-3 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-pyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-92-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-4'-[(tetrahydro-2H-thiopyran-4-yl)oxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 858097-94-6 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[3-(diethoxyphosphinyl)propoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-98-0 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-6-(1-methylethoxy)-4'-[(3-methyl-3-oxetanyl)methoxy][1,1'-biphenyl]-3-yl]methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 858097-99-1 HCAPLUS
CN Benzenepropanoic acid, 4-[[4'-[2-(ethylsulfonyl)ethoxy]-2',6'-dimethyl[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:587179 HCAPLUS
DOCUMENT NUMBER: 143:97158
TITLE: Preparation of biphenyl compounds as PPARδ agonists, pharmaceuticals containing them, and their uses
INVENTOR(S): Uchiyama, Katsuya; Miyauchi, Hiroshi; Uno, Shinsaku
PATENT ASSIGNEE(S): Sumitomo Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.
CODEN: JKXXAF

Updated Search

10518679

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005179281	A2	20050707	JP 2003-423747	20031219
PRIORITY APPLN. INFO.:			JP 2003-423747	20031219

OTHER SOURCE(S): MARPAT 143:97158
GI



I

AB Claimed are biphenyl compds. I [R1-R8 = H, OH, (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6alkoxy, C6-10 arylsulfonyloxy, C5-7 cyclic aminocarbonyl, cyano, halo, etc.; adjacent 2 groups among R1-R8 may be linked to each other to form a condensed benzene, 5-6-membered (un)saturated carbocyclyl optionally containing 1-2 heteroatom; R9 = H, F, (un)substituted C1-6 alkyl, C1-11 acyl, carboxy; R9 and R10 may be linked to form C3-7 cycloalkane ring; R9 and/or R10 = substituent; R11, R12 = H, F, (un)substituted C1-6 alkyl; R11 and R12 may be linked to form C3-7 cycloalkane ring; W1, W2 = O, S, NR16 [R16 = H, (un)substituted C1-6 alkyl]; R13 = carboxy, (un)substituted C2-7 alkoxycarbonyl, C3-7 alkenyloxycarbonyl, carbamoyl, etc.] or their salts. Also claimed are pharmaceuticals, PPARδ activators, blood HDL concentration-increasing agents, agents for treating low blood HDL, and antiarteriosclerotic agents containing I (salts). Thus, (+)-[4-[1-[4-fluoro-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]ethoxy]-2-methylphenoxy]acetic acid (II), obtained by chiral chromatog. resolution of the racemate which was prepared from 5-bromo-2-fluorobenzaldehyde and 4-(trifluoromethyl)phenylboronic acid with 5 steps, showed PPARδ-agonistic activity at ED50 of 14 nM. Oral administration of II to mice for 6 wk showed 28% increase in blood HDL cholesterol concentration

IT 857086-21-6P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of biphenyl compds. as PPARδ agonists for increasing blood HDL and treating arteriosclerosis)

RN 857086-21-6 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



IT 857086-34-1P 857086-35-2P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biphenyl compds. as PPARδ agonists for increasing blood HDL and treating arteriosclerosis)
RN 857086-34-1 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-2-methylphenoxy]-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 857086-35-2 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethoxy]-2-methylphenoxy]-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).



IT 857086-22-7P 857086-23-8P 857086-24-9P
857086-25-0P 857086-26-1P 857086-27-2P
857086-28-3P 857086-29-4P 857086-30-7P
857086-31-8P 857086-32-9P 857086-33-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

Updated Search

(preparation of biphenyl compds. as PPARδ agonists for increasing blood HDL and treating arteriosclerosis)

RN 857086-22-7 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]propoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-23-8 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]butoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-24-9 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methylpropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-25-0 HCAPLUS
CN Acetic acid, [4-[[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]pentyl]oxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 857086-26-1 HCAPLUS
CN Acetic acid, [4-[[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]phenylmethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-27-2 HCAPLUS
CN [1,1'-Biphenyl]-3-acetic acid, α-[4-(carboxymethoxy)-3-methylphenoxy]-4-fluoro-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 857086-28-3 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-hydroxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-29-4 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-methoxyethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 857086-30-7 HCAPLUS
CN Acetic acid, [4-[2-amino-1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-oxoethoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-31-8 HCAPLUS
CN Acetic acid, [4-[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-2-oxopropoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-32-9 HCAPLUS
CN Acetic acid, [4-[cyano[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 857086-33-0 HCAPLUS
CN Acetic acid, [4-[[1-[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]ethyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



L7 ANSWER 7 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:493499 HCAPLUS
DOCUMENT NUMBER: 143:48037
TITLE: Receptor function regulating agent
INVENTOR(S): Fukatsu, Kohji; Fujii, Ryo; Kobayashi, Makoto; Yonemori, Jinichi; Tanaka, Toshio
PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
SOURCE: PCT Int. Appl., 344 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051373	A1	20050609	WO 2004-JP17996	20041126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2547430	AA	20050609	CA 2004-2547430	20041126
EP 1688138	A1	20060809	EP 2004-799921	20041126
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				

PRIORITY APPLN. INFO.: JP 2003-394848 A 20031126
WO 2004-JP17996 W 20041126

AB A 14273 receptor function regulating agent useful as a preventive/therapeutic agent for diabetes, hyperlipemia, etc. There is provided a 14273 receptor function regulating agent comprising a compound having a group capable of releasing an aromatic ring and a cation.

IT 853010-30-7P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(receptor function regulating agent)

RN 853010-30-7 HCAPLUS

CN Benzenepropanoic acid, 4-[(4'-chloro[1,1'-biphenyl]-3-yl)methoxy]-3,5-difluoro- (9CI) (CA INDEX NAME)

Updated Search

10518679



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:409470 HCAPLUS
DOCUMENT NUMBER: 142:463453
TITLE: Preparation of 4-((phenoxyalkyl)thio)phenoxyacetic acids and analogs as PPARδ agonists for treating conditions like dyslipidemia
INVENTOR(S): Kuo, Gee-Hong; Zhang, Rui; Wang, Aihua; Deangelis, Alan R.
PATENT ASSIGNEE(S): Janssen Pharmaceutica, N.V., Belg.
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042478	A2	20050512	WO 2004-US30375	20040916
WO 2005042478	A3	20050721		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004285849	A1	20050512	AU 2004-285849	20040916
CA 2539446	AA	20050512	CA 2004-2539446	20040916
US 2005124698	A1	20050609	US 2004-942478	20040916
EP 1667964	A2	20060614	EP 2004-816875	20040916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004014268	A	20061107	BR 2004-14268	20040916
NO 2006001728	A	20060619	NO 2006-1728	20060419
PRIORITY APPLN. INFO.:			US 2003-504146P P	20030919
			WO 2004-US30375 W	20040916

OTHER SOURCE(S): MARPAT 142:463453
GI

Updated Search

10518679



AB The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs (shown as I; variables defined below; e.g. [2-methyl-4-[[2-methyl-3-[(4-trifluoromethylphenyl)oxy]propyl]sulfanyl]phenoxy]acetic acid (II)), compns. containing them, and methods of using them as PPARδ modulators to treat or inhibit the progression of, for example, dyslipidemia. For I: X = a covalent bond, S, or O; Y is S or O; ---W--- represents a =CH-, -CH=, -CH2-, -CH2CH2-, =CHCH2-, -CH2CH=, =CHCH=, and -CH:CH-; Z = O, CH, and CH2, provided when Y is O, Z is O; R1 and R2 = H, C1-3 alkyl, C1-3 alkoxy, halo, and NRaRb wherein; Ra and Rb = H or C1-3 alkyl; R3 and R4 = H, halo, cyano, hydroxy, acetyl, C1-5 alkyl, C1-4 alkoxy, and NRcRd wherein Rc and Rd = H or C1-3 alkyl, provided that R3 and R4 are not both H; R5 = halo, Ph, phenoxy, (phenyl)C1-5alkoxy, (phenyl)C1-5-alkyl, C2-5heteroaryloxy, C2-5heteroarylC1-5alkoxy, C2-5heterocyclyloxy, C1-9 alkyl, C1-8 alkoxy, C2-9 alkenyl, C2-9 alkenyloxy, C2-9 alkynyl, C2-9 alkynyloxy, C3-7 cycloalkyl, C3-7 cycloalkoxy, C3-7cycloalkyl-C1-7-alkyl, C3-7cycloalkyl-C1-7-alkoxy, C3-7cycloalkyloxy-C1-6alkyl, C1-6alkoxy-C1-6alkyl, C1-5alkoxy-C1-5alkoxy, or C3-7cycloalkyloxy-C1-7alkoxy; R6 is H when ---W--- = -CH=, -CH2-, -CH2CH2-, -CH2CH=, and -CH:CH-, or R6 is absent when ---W--- = =CH-, =CHCH2-, and =CHCH=; and n = 1 or 2. EC50 values for PPARδ for 47 examples of I are tabulated. Although the methods of preparation are not claimed, .apprx.40 example prepns. are included. For example, II was prepared from (4-mercapto-2-methylphenoxy)acetic acid Et ester and the mesylate of 2-methyl-3-[4-(trifluoromethyl)phenoxy]-1-propanol followed by saponification; prepns. of the starting materials are also described.

IT 851529-54-9P, [2-Methyl-4-[[[4-(4-trifluoromethylphenyl)-3,6-dihydro-2H-pyran-2-yl]methyl]sulfanyl]phenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 4-((phenoxyalkyl)thio)phenoxyacetic acids and analogs as PPARδ agonists for treating conditions like dyslipidemia)

RN 851529-54-9 HCAPLUS

CN Acetic acid, [4-[[[3,6-dihydro-4-[4-(trifluoromethyl)phenyl]-2H-pyran-2-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 9 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:394834 HCAPLUS

Updated Search

10518679

DOCUMENT NUMBER: 142:447218
TITLE: Preparation of 4-[(thiadiazolylalkyl)thio]phenoxyaceti c acids and analogs for treating PPAR mediated conditions
INVENTOR(S): Kuo, Gee-Hong; Shen, Lan; Wang, Aihua; Zhang, Yan
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: U.S. Pat. Appl. Publ., 59 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096362	A1	20050505	US 2004-975785	20041028
US 7015329	B2	20060321		
AU 2004285530	A1	20050512	AU 2004-285530	20041028
CA 2544317	AA	20050512	CA 2004-2544317	20041028
WO 2005041959	A1	20050512	WO 2004-US36028	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1684752	A1	20060802	EP 2004-796767	20041028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 2006074246	A1	20060406	US 2005-274656	20051115
NO 2006002511	A	20060727	NO 2006-2511	20060531

PRIORITY APPLN. INFO.:

US 2003-516561P	P	20031031
US 2004-975785	A3	20041028
WO 2004-US36028	W	20041028

OTHER SOURCE(S): MARPAT 142:447218
GI

Updated Search



I



II

AB The title compds. I [m = 1-3; n = 0-1; X = S, O; Y = S, CH2, O; R1, R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, halo, CN, etc.; R5, R6 = H, alkyl, alkoxy, etc.; or R5 and R6 together may form spiro cycloalkyl or spiro 5-6 membered heterocyclyl having 1-3 heteroatoms selected from O, S, and N; R7, R8 = H, alkyl, cycloalkyl], useful as PPAR modulators to treat or inhibit the progression of, for example, dyslipidemia, were prepared E.g., a multi-step synthesis of II, starting from Et (2-methylphenoxy)acetate, was given. Compound II showed EC50 of 10 nM and of 468 nM against PPARδ and PPARα, resp. The pharmaceutical compns. comprising I are disclosed.

IT 851224-78-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[(thiadiazolylalkyl)thio]phenoxyacetic acids and analogs for treating PPAR mediated conditions)

RN 851224-78-7 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[5-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search

10518679

L7 ANSWER 10 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:394829 HCAPLUS
DOCUMENT NUMBER: 142:463605
TITLE: Preparation aryloxyacetic acids and related compounds as PPARδ and PPARα agonists
INVENTOR(S): Ackermann, Jean; Aebi, Johannes; Binggeli, Alfred; Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Wright, Matthew Blake
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096337	A1	20050505	US 2004-978155	20041029
US 7115611	B2	20061003		
AU 2004291262	A1	20050602	AU 2004-291262	20041028
CA 2543249	AA	20050602	CA 2004-2543249	20041028
WO 2005049573	A1	20050602	WO 2004-EP12217	20041028
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1682508	A1	20060726	EP 2004-790987	20041028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
NO 2006002135	A	20060524	NO 2006-2135	20060512
PRIORITY APPLN. INFO.:			EP 2003-104081 A	20031105
			EP 2004-100759 A	20040226
			WO 2004-EP12217 W	20041028

OTHER SOURCE(S): MARPAT 142:463605
GI

Updated Search

10518679



I



II

AB Title compds. I [X = O, S, CH2; R1 = H, alkyl; R2 = H, alkyl with provisos; R3 = H, alkyl; R4, R8 = H, alkyl, cycloalkyl, etc.; R5, R6, R7 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, saponification of Et ester II (Z = OEt), afforded acid II (Z = OH) as a light yellow solid. In PPARα receptor binding assays, 3-examples of compds. I exhibited IC50 values ranging from 0.013-0.289 μmmol/l. Compds. I are claimed to be useful for the treatment of diseases modulated by PPARδ and PPARα agonist.

IT 851505-97-0P 851505-98-1P 851506-06-4P
851506-07-5P 851506-08-6P 851506-11-1P
851506-12-2P 851506-13-3P 851506-14-4P
851506-23-5P 851506-24-6P 851506-25-7P
851506-26-8P 851506-27-9P 851506-29-1P
851506-30-4P 851506-32-6P 851506-34-8P
851506-35-9P 851506-36-0P 851506-37-1P
851506-38-2P 851506-39-3P 851506-40-6P
851506-51-9P 851506-61-1P 851506-62-2P
851506-63-3P 851506-79-1P 851506-80-4P
851506-81-5P 851506-97-3P 851507-09-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation aryloxyacetic acids and related compds. as PPARδ and PPARα agonists)

RN 851505-97-0 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851505-98-1 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-06-4 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-07-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]propyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-08-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851506-11-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]butyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-12-2 HCAPLUS
CN Acetic acid, [4-[[cyclopentyl[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 851506-13-3 HCAPLUS
CN Propanoic acid, 2-[4-[[6-[4-fluoro-3-(trifluoromethyl)phenyl]-2-methyl-3-pyridinyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-14-4 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX

Updated Search

NAME)



RN 851506-23-5 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-24-6 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-25-7 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-26-8 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-methyl-6-[4-

Updated Search

(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-27-9 HCAPLUS
CN Propanoic acid, 2-[4-[[6-[3-fluoro-4-(trifluoromethyl)phenyl]-2-methyl-3-pyridinyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-29-1 HCAPLUS
CN Propanoic acid, 2-[4-[[2-cyclopropyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



Updated Search

RN 851506-30-4 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[1-[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-32-6 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[2-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-34-8 HCAPLUS
CN Propanoic acid, 2-[4-[[2-(methoxymethyl)-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-35-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851506-36-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-37-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[2-methyl-6-[3-(trifluoromethyl)phenyl]-3-pyridinyl]butoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-38-2 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]propoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851506-39-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851506-40-6 HCAPLUS
CN Propanoic acid, 2-[4-[[2-[(dimethylamino)methyl]-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]-2-methylphenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-51-9 HCAPLUS
CN Benzenepropanoic acid, 3-ethoxy-4-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)



RN 851506-61-1 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 851506-62-2 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851506-63-3 HCAPLUS
CN Benzenepropanoic acid, 3-methyl-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]- (9CI) (CA INDEX NAME)



RN 851506-79-1 HCAPLUS
CN Propanoic acid, 2-[2-methoxy-4-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-80-4 HCAPLUS
CN Propanoic acid, 2-[2-methoxy-4-[1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 851506-81-5 HCAPLUS
CN Benzenepropanoic acid, 2-methoxy-4-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 851506-97-3 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[4-(trifluoromethyl)-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 851507-09-0 HCAPLUS
CN Benzenepropanoic acid, 2-methyl-4-[3-methyl-1-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]butoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:1019618 HCAPLUS
DOCUMENT NUMBER: 142:69141
TITLE: Methods of identifying non-specific inhibitors of biomolecules
INVENTOR(S): Shoichet, Brian K.; McGovern, Susan L.
PATENT ASSIGNEE(S): Northwestern University, USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004234942	A1	20041125	US 2002-171814	20020614

Updated Search

10518679

US 6887658 B2 20050503
PRIORITY APPLN. INFO.: US 2001-298527P P 20010615

AB The invention provides methods of identifying compds. that non-specifically inhibit biol. reactions. The invention further includes kits that facilitate this identification. In addition, compilations of compds. for use in high throughput drug screening that have been evaluated by the disclosed methodol. are also part of the d invention. The invention provides methods for identifying a false pos. in a screening assay by measuring the activity of at least one biol. activity in the presence and absence of a small mol. compound capable of inhibiting aggregate formation, e.g., digitonin.

IT 813420-84-7
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(methods of identifying non-specific inhibitors of biomols.)

RN 813420-84-7 HCAPLUS

CN 4-Pyridinecarboxylic acid, 2,6-bis(4-chlorophenyl)-, 4-(1-carboxy-3-methylbutoxy)phenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:412803 HCAPLUS
DOCUMENT NUMBER: 141:1264
TITLE: Receptor function controlling agent
INVENTOR(S): Fukatsu, Kohji; Sasaki, Shinobu; Hinuma, Shuji; Ito, Yasuaki; Suzuki, Nobuhiro; Harada, Masataka; Yasuma, Tsuneo
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 442 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041266	A1	20040521	WO 2003-JP14139	20031106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

Updated Search

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2505322	AA	20040521	CA 2003-2505322		20031106
AU 2003277576	A1	20040607	AU 2003-277576		20031106
JP 2005015461	A2	20050120	JP 2003-376833		20031106
EP 1559422	A1	20050803	EP 2003-810621		20031106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1735408	A	20060215	CN 2003-80108260		20031106
PRIORITY APPLN. INFO.:			JP 2002-324632	A	20021108
			JP 2003-16889	A	20030127
			JP 2003-153986	A	20030530
			WO 2003-JP14139	W	20031106

OTHER SOURCE(S): MARPAT 141:1264

AB A GPR40 receptor function controlling agent which contains a compound having an aromatic ring and a group capable of releasing a cation and is useful as a insulin secretion promoting agent or a preventive/remedy for diabetes, etc.

IT 691900-29-5P 691900-39-7P 691900-43-3P
691901-52-7P 691901-54-9P 691901-56-1P
691901-58-3P 691901-74-3P 691901-94-7P
691902-31-5P 691902-33-7P 691902-35-9P
691902-37-1P 691902-39-3P 691902-41-7P
691902-56-4P 691902-57-5P 691902-58-6P
691902-66-6P 691902-68-8P 691902-70-2P
691902-74-6P 691903-19-2P 691903-66-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GPR40 receptor function controlling agents as antidiabetics)

RN 691900-29-5 HCAPLUS

CN Benzenepropanoic acid, 4-[(4'-chloro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691900-39-7 HCAPLUS

CN Benzenepropanoic acid, 4-[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691900-43-3 HCAPLUS

CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-

Updated Search

(9CI) (CA INDEX NAME)



RN 691901-52-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(3'-chloro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691901-54-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-chloro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691901-56-1 HCAPLUS
CN Benzenepropanoic acid, 4-[(3'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691901-58-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(3'-fluoro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 691901-74-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-fluoro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691901-94-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-31-5 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 691902-33-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 691902-35-9 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2-methoxy- (9CI) (CA INDEX NAME)

Updated Search



RN 691902-37-1 HCAPLUS
CN Benzenepropanoic acid, 2-chloro-4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-39-3 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-41-7 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-4-yl)methoxy]-2-fluoro- (9CI) (CA INDEX NAME)



RN 691902-56-4 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-methyl-6'-propyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



RN 691902-57-5 HCAPLUS
CN Benzenepropanoic acid, 4-[[2'-methyl-6'-(2-methylpropyl)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



RN 691902-58-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2'-ethyl-6'-methyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-66-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2,2',6'-trimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-68-8 HCAPLUS
CN Benzenepropanoic acid, 4-[(6-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 691902-70-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(4-methoxy-2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691902-74-6 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-dimethyl[1,1'-biphenyl]-3-yl)methoxy]-2,6-difluoro- (9CI) (CA INDEX NAME)



RN 691903-19-2 HCAPLUS
CN Benzenepropanoic acid, 4-[(2',6'-difluoro[1,1'-biphenyl]-3-yl)methoxy]- (9CI) (CA INDEX NAME)



RN 691903-66-9 HCAPLUS
CN Benzenepropanoic acid, 4-[[2',6'-dimethyl-6-(phenylmethoxy)[1,1'-biphenyl]-3-yl]methoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:60458 HCAPLUS

Updated Search

10518679

DOCUMENT NUMBER: 140:111286
TITLE: Preparation of biaryl derivatives as agonists of peroxisome proliferator activated receptor δ (PPARδ)
INVENTOR(S): Miyauchi, Hiroshi; Uchiyama, Katsuya; Ban, Hitoshi; Morishita, Koji; Muraoka, Masami
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004007439	A1	20040122	WO 2003-JP8683	20030708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003281040	A1	20040202	AU 2003-281040	20030708
PRIORITY APPLN. INFO.:			JP 2002-201738 A	20020710
			JP 2002-268082 A	20020913
			WO 2003-JP8683 W	20030708

OTHER SOURCE(S): MARPAT 140:111286
GI



I

AB Compds. represented by the following general formula (I) or salt thereof [wherein R1-R8 = H, HO, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C1-6 alkoxy, C1-11 acyloxy, C2-7 alkoxycarbonyl, C1-6 alkylcarbamoyl, di(C1-6 alkyl)carbamoyl, C1-6 alkylsulfonyloxy, or C6-10 arylsulfonyloxy, carbamoyl, CO2H, cyano, halo, etc.; or if R1 and R2, R3 and R4, R5 and R7, or R6 and R8 are adjacent to each other, they together from an (un)substituted benzene ring, (un)saturated 5- or 6-membered carbocyclic or heterocyclic ring containing 1 or 2 heteroatoms in the latter; R9, R10 = H, (un)substituted C1-6 alkyl; R11, R12 = H, F, (un)substituted C1-6 alkyl; or R11 and R12 together with the carbon atoms to which they are attached form a (un)substituted C3-7 cycloalkane ring; W1, W2 = O, S, NR16; wherein R16 = H, (un)substituted C1-6 alkyl; A = CR3, N; R13 = CO2H, each

Updated Search

(un)substituted C2-7 alkoxycarbonyl, C3-7 alkenyloxycarbonyl, C7-16 arylalkoxycarbonyl, carbamoyl, or (C3-6 cycloalkyl)carbamoyl, tetrazolyl, etc.] are prepared These compds., e.g. [4-[[[4-fluoro-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]methyl]thio]-2-methylphenoxy]acetic acid (II), N-(2-furylmethyl)-2-[4-[[[4-fluoro-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]methyl]thio]-2-methylphenoxy]acetamide (III), 2-[4-[[[4-fluoro-4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]methyl]thio]-2-methylphenoxy]-N-(pyridin-2-ylmethyl)acetamide (IV), and [4-[[[3-fluoro-6-[4-(trifluoromethyl)phenyl]pyridin-2-yl]methyl]thio]-2-methylphenoxy]acetic acid have an agonistic activity to peroxisome proliferator activated receptor δ (PPARδ) and, therefore, are useful as agents elevating blood high d. lipoprotein (HDL) level, remedies for hypo-HDL cholesterolemia and/or remedies for arteriosclerosis. Thus, II, III, and IV inhibited luciferase activity with EC50 of 23, 10, and 13 nM, resp., in COS-1 cells introduced with 3 plasmids including PPARδ-LBD (ligand binding domain) fused to Gal-4 DNA binding domain, firefly-derived luciferase reporter having Gal-4 binding DNA sequence in the promotor domain, and luciferase expression plasmid.

IT 638215-22-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of biaryl derivs. as agonists of peroxisome proliferator activated receptor δ (PPARδ) and agents elevating blood high d. lipoprotein (HDL) level for treatment of arteriosclerosis)

RN 638215-22-2 HCAPLUS

CN Acetic acid, [2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



IT 638215-23-3P 638215-26-6P 648437-33-6P
648437-34-7P 648437-35-8P 648437-36-9P
648437-37-0P 648437-38-1P 648437-39-2P
648437-40-5P 648437-41-6P 648437-42-7P
648437-43-8P 648437-44-9P 648437-45-0P
648437-46-1P 648437-47-2P 648437-48-3P
648437-49-4P 648437-50-7P 648437-51-8P
648437-52-9P 648437-53-0P 648437-54-1P
648437-55-2P 648437-56-3P 648437-57-4P
648437-58-5P 648437-59-6P 648437-60-9P
648437-61-0P 648437-63-2P 648437-64-3P
648437-65-4P 648437-66-5P 648437-67-6P
648437-68-7P 648437-69-8P 648437-70-1P
648437-71-2P 648437-72-3P 648437-73-4P
648437-74-5P 648437-75-6P 648437-76-7P
648437-77-8P 648437-78-9P 648437-79-0P
648437-80-3P 648437-81-4P 648437-82-5P
648437-83-6P 648437-84-7P 648437-85-8P
648437-86-9P 648437-87-0P 648437-88-1P
648437-89-2P 648437-90-5P 648437-91-6P

Updated Search

648437-92-7P 648437-93-8P 648437-94-9P
648437-95-0P 648437-97-2P 648437-98-3P
648437-99-4P 648438-00-0P 648438-01-1P
648438-04-4P 648438-05-5P 648438-07-7P
648438-08-8P 648438-09-9P 648438-10-2P
648438-11-3P 648438-12-4P 648438-14-6P
648438-15-7P 648438-44-2P 648438-45-3P
648438-46-4P 648438-47-5P 648438-48-6P
648438-49-7P 648438-50-0P 648438-51-1P
648438-52-2P 648438-53-3P 648438-54-4P
648438-61-3P 648438-62-4P 648438-63-5P
648438-64-6P 648438-65-7P 648438-66-8P
648438-67-9P 648438-68-0P 648438-75-9P
648438-76-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of biaryl derivs. as agonists of peroxisome proliferator activated receptor δ (PPARδ) and agents elevating blood high d. lipoprotein (HDL) level for treatment of arteriosclerosis)

RN 638215-23-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 638215-26-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-33-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[5-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-34-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[6-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-35-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-36-9 HCAPLUS
CN Acetic acid, [4-[[[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-37-0 HCAPLUS
CN Acetic acid, [4-[[[5-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-38-1 HCAPLUS
CN Acetic acid, [4-[[[6-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-39-2 HCAPLUS
CN Acetic acid, [4-[[[2-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-40-5 HCAPLUS
CN Acetic acid, [4-[[[4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-41-6 HCAPLUS
CN Acetic acid, [4-[[[6-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-42-7 HCAPLUS
CN Acetic acid, [4-[[[2-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-43-8 HCAPLUS
CN Acetic acid, [4-[[[4-ethoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-44-9 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4-(1-methylethoxy)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-45-0 HCAPLUS
CN Acetic acid, [4-[[[4-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-46-1 HCAPLUS
CN Acetic acid, [4-[[[4,5-dimethoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-47-2 HCAPLUS
CN Acetic acid, [4-[[[5,6-dimethoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-48-3 HCAPLUS
CN Acetic acid, [4-[[(2',4'-difluoro-4-methoxy[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 648437-49-4 HCAPLUS
CN Acetic acid, [4-[[[4-hydroxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-50-7 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3-[[[4-(carboxymethoxy)-3-methylphenyl]thio]methyl]-4'-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 648437-51-8 HCAPLUS
CN Acetic acid, [4-[[[4-[(dimethylamino)carbonyl]-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-52-9 HCAPLUS
CN Acetic acid, [4-[[[4-(hydroxymethyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-53-0 HCAPLUS
CN Acetic acid, [4-[[[2,4-difluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-54-1 HCAPLUS
CN Acetic acid, [4-[[[4-fluoro-2-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-55-2 HCAPLUS
CN Acetic acid, [4-[[[4-fluoro-5-hydroxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-56-3 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 5-[[[4-(carboxymethoxy)-3-methylphenyl]thio]methyl]-4-fluoro-4'-(trifluoromethyl)- (9CI) (CA INDEX

Updated Search

NAME)



RN 648437-57-4 HCAPLUS
CN Acetic acid, [4-[[[4-fluoro-5-(hydroxymethyl)-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648437-58-5 HCAPLUS
CN Propanoic acid, 2-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-59-6 HCAPLUS
CN Butanoic acid, 3-methyl-2-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-60-9 HCAPLUS

Updated Search

10518679

CN Propanoic acid, 2-methyl-2-[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-61-0 HCAPLUS
CN Acetic acid, fluoro[4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-63-2 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-64-3 HCAPLUS
CN Acetic acid, [2-ethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-65-4 HCAPLUS
CN Acetic acid, [2-(1-methylethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-66-5 HCAPLUS
CN Acetic acid, [2-(1,1-dimethylethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-67-6 HCAPLUS
CN Acetic acid, [2,3-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-68-7 HCAPLUS
CN Acetic acid, [2-fluoro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-69-8 HCAPLUS
CN Acetic acid, [2,6-difluoro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-70-1 HCAPLUS
CN Acetic acid, [2-chloro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-71-2 HCAPLUS
CN Acetic acid, [2-methoxy-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-72-3 HCAPLUS
CN Acetic acid, [3-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-73-4 HCAPLUS
CN Acetic acid, [3-fluoro-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-74-5 HCAPLUS
CN Acetic acid, [2-bromo-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-75-6 HCAPLUS
CN Acetic acid, [2-(trifluoromethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-76-7 HCAPLUS
CN Acetic acid, [2,5-dimethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-77-8 HCAPLUS
CN Acetic acid, [2-(methoxymethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-78-9 HCAPLUS
CN Acetic acid, [2-(hydroxymethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-79-0 HCAPLUS
CN Acetic acid, [2-cyano-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-80-3 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 648437-81-4 HCAPLUS
CN Acetic acid, [2-(aminocarbonyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-82-5 HCAPLUS
CN Acetic acid, [2-[(dimethylamino)carbonyl]-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-83-6 HCAPLUS
CN Acetic acid, [2-ethenyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-84-7 HCAPLUS
CN Acetic acid, [2-(2-propenyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-85-8 HCAPLUS
CN Acetic acid, [3-ethyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-86-9 HCAPLUS
CN Acetic acid, [3-bromo-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-87-0 HCAPLUS
CN Acetic acid, [3-(trifluoromethyl)-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-88-1 HCAPLUS
CN Benzoic acid, 5-(carboxymethoxy)-2-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 648437-89-2 HCAPLUS
CN Acetic acid, [5-cyano-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 648437-90-5 HCAPLUS
CN Acetic acid, [5-fluoro-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-91-6 HCAPLUS
CN Acetic acid, [2-chloro-6-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-92-7 HCAPLUS
CN Acetic acid, [5-chloro-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-93-8 HCAPLUS
CN Acetic acid, [3-(hydroxymethyl)-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-94-9 HCAPLUS
CN Acetic acid, [5-(hydroxymethyl)-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648437-95-0 HCAPLUS
CN Acetic acid, [5-(methoxymethyl)-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648437-97-2 HCAPLUS
CN Benzoic acid, 2-(carboxymethoxy)-3-methyl-5-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 648437-98-3 HCAPLUS
CN Benzoic acid, 3-(carboxymethoxy)-2-methyl-6-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]- (9CI) (CA INDEX NAME)



RN 648437-99-4 HCAPLUS
CN Benzoic acid, 5-(carboxymethoxy)-4-methyl-2-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 648438-00-0 HCAPLUS
CN Acetic acid, [3-(aminocarbonyl)-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-01-1 HCAPLUS
CN Acetic acid, [5-(aminocarbonyl)-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-04-4 HCAPLUS
CN Acetic acid, [2-bromo-4-[[[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-05-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[(4'-methyl[1,1'-biphenyl]-3-yl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-07-7 HCAPLUS

Updated Search

CN Acetic acid, [2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-08-8 HCAPLUS
CN Acetic acid, [4-[[3'-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-09-9 HCAPLUS
CN Acetic acid, [3-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-10-2 HCAPLUS
CN Propanoic acid, 2-[2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-11-3 HCAPLUS
CN Butanoic acid, 3-methyl-2-[2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648438-12-4 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-14-6 HCAPLUS
CN Acetic acid, [4-[[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-15-7 HCAPLUS
CN Acetic acid, [4-[[4-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]-3-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-44-2 HCAPLUS
CN Acetic acid, [4-[[[3-fluoro-6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648438-45-3 HCAPLUS
CN Acetic acid, [2-methyl-4-[[6-[4-(trifluoromethyl)phenyl]-2-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-46-4 HCAPLUS
CN Acetic acid, [4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-47-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-48-6 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[2'-(trifluoromethyl)[1,1'-biphenyl]-3-

Updated Search

yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-49-7 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(4'-methyl[1,1'-biphenyl]-3-yl)methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-50-0 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(3'-methyl[1,1'-biphenyl]-3-yl)methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-51-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[[(2'-methyl[1,1'-biphenyl]-3-yl)methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 648438-52-2 HCAPLUS
CN Acetic acid, [4-[[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648438-53-3 HCAPLUS
CN Acetic acid, [4-[[(3'-fluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-54-4 HCAPLUS
CN Acetic acid, [4-[[(2'-fluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-61-3 HCAPLUS
CN Acetic acid, [4-[[(3',4'-dimethyl[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-62-4 HCAPLUS
CN Acetic acid, [4-[[(2',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 648438-63-5 HCAPLUS
CN Acetic acid, [4-[[(3',4'-difluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-64-6 HCAPLUS
CN Acetic acid, [4-[[(3',5'-difluoro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-65-7 HCAPLUS
CN Acetic acid, [4-[[(2',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-66-8 HCAPLUS
CN Acetic acid, [4-[[(3',4'-dichloro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



RN 648438-67-9 HCAPLUS
CN Acetic acid, [4-[[(3',5'-dichloro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-68-0 HCAPLUS
CN Acetic acid, [4-[[[3'-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-75-9 HCAPLUS
CN Acetic acid, [4-[[(4'-chloro[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 648438-76-0 HCAPLUS
CN Acetic acid, [4-[[(4'-bromo[1,1'-biphenyl]-3-yl)methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:818386 HCAPLUS
DOCUMENT NUMBER: 139:323345
TITLE: Preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity
INVENTOR(S): Filzen, Gary Frederick; Trivedi, Bharat Kalidas; Geyer, Andrew George; Unangst, Paul Charles; Bratton, Larry Don; Auerbach, Bruce Jeffrey
PATENT ASSIGNEE(S): Warner-Lambert Company LLC, USA
SOURCE: PCT Int. Appl., 246 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003084916	A2	20031016	WO 2003-IB1121	20030324
WO 2003084916	A3	20031224		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003225158	A1	20031204	US 2003-347749	20030122
US 6875780	B2	20050405		
CA 2481246	AA	20031016	CA 2003-2481246	20030324
AU 2003212578	A1	20031020	AU 2003-212578	20030324
EP 1494989	A2	20050112	EP 2003-708403	20030324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003009169	A	20050125	BR 2003-9169	20030324
JP 2005521741	T2	20050721	JP 2003-582115	20030324
JP 3816922	B2	20060830		
CN 1649820	A	20050803	CN 2003-809791	20030324
US 2005113440	A1	20050526	US 2004-979629	20041102
US 6964983	B2	20051115		
US 2005153996	A1	20050714	US 2004-979617	20041102
US 6939875	B2	20050906		
NO 2004004795	A	20041104	NO 2004-4795	20041104
JP 2006151985	A2	20060615	JP 2005-360431	20051214

Updated Search

10518679

PRIORITY APPLN. INFO.:

US 2002-370508P	P	20020405
US 2002-386026P	P	20020605
US 2003-347749	A3	20030122
JP 2003-582115	A3	20030324
WO 2003-IB1121	W	20030324
US 2003-463641P	P	20030417

OTHER SOURCE(S): MARPAT 139:323345

GI



I



II

AB The title compds. [I; X0, X1 = O, S, CH2, CH:CH, etc.; Ar1, Ar2 = (un)substituted (hetero)aryl, provided that Ar1 is not thiazolyl or oxazolyl; V1 is absent or V1 = (un)saturated (un)substituted hydrocarbon chain having 1-4 atoms; R1, R2 = H, alkyl, alkoxy, etc.; R3, R4 = H, alkyl, alkoxy, etc.; q, r = 0-6] that alter PPAR activity, were prepared and formulated. E.g., a 7-step synthesis of II (starting from 2-hydroxy-4-methoxybenzaldehyde) which showed EC50 of >0-300 nM against PPARα and PPARβ, was given. The invention also discloses pharmaceutically acceptable compns. comprising the compds. I or their salts, and methods of using them as therapeutic agents for treating or preventing hyperlipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal.

IT 613238-23-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity)

RN 613238-23-6 HCAPLUS

CN Acetic acid, [5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



IT 613238-22-5P 613238-24-7P 613238-25-8P
613238-26-9P 613238-27-0P 613238-28-1P
613238-29-2P 613238-38-3P 613238-39-4P
613238-40-7P 613238-41-8P 613238-42-9P
613238-44-1P 613238-57-6P 613238-58-7P
613238-68-9P 613238-69-0P 613238-70-3P
613238-71-4P 613239-19-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyacetic acids and indanyloxyacetic acids that modulate PPAR activity)

RN 613238-22-5 HCAPLUS
CN Acetic acid, [2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-24-7 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[(2',4',6'-trimethyl[1,1'-biphenyl]-4-yl)methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-25-8 HCAPLUS
CN Acetic acid, [4-[[[4'-chloro-3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 613238-26-9 HCAPLUS
CN Acetic acid, [4-[[(2',4'-dichloro[1,1'-biphenyl]-4-yl)methyl]thio]-5-methoxy-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 613238-27-0 HCAPLUS
CN Acetic acid, [4-[[(3',4'-dichloro[1,1'-biphenyl]-4-yl)methyl]thio]-5-methoxy-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 613238-28-1 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-29-2 HCAPLUS
CN Acetic acid, [4-[[(4'-fluoro[1,1'-biphenyl]-4-yl)methyl]thio]-5-methoxy-2-methylphenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 613238-38-3 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-39-4 HCAPLUS
CN Acetic acid, [5-chloro-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-40-7 HCAPLUS
CN Acetic acid, [3-methoxy-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-41-8 HCAPLUS
CN Acetic acid, [2-methyl-4-[[2-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 613238-42-9 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[2-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-44-1 HCAPLUS
CN Acetic acid, [2-methyl-4-[2-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-57-6 HCAPLUS
CN Acetic acid, [5-hydroxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-58-7 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[3-methyl-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search



RN 613238-68-9 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-69-0 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]sulfonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-70-3 HCAPLUS
CN Acetic acid, [5-methoxy-2-methyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]sulfinyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 613238-71-4 HCAPLUS
CN Acetic acid, [2-propyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)

Updated Search

10518679



RN 613239-19-3 HCAPLUS
CN Acetic acid, [2-butyl-4-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



L7 ANSWER 15 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:173582 HCAPLUS
DOCUMENT NUMBER: 138:221586
TITLE: Preparation of azoles as oral antidiabetic agents.
INVENTOR(S): Bigge, Christopher Franklin; Bridges, Alesander James; Casimiro-Garcia, Augustin; Fakhoury, Stephen Alan; Lee, Helen Tsenwhei; Reed, Jessica Elizabeth; Schaum, Robert Philipp; Schlosser, Kevin Matthew; Sexton, Karen Elaine; Zhou, Hairong
PATENT ASSIGNEE(S): Warner Lambert Co., USA
SOURCE: PCT Int. Appl., 333 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018553	A1	20030306	WO 2002-IB2843	20020715
WO 2003018553	C1	20040408		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2458621	AA	20030306	CA 2002-2458621	20020715
EP 1423363	A1	20040602	EP 2002-745739	20020715
EP 1423363	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

Updated Search

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002012069	A	20040720	BR 2002-12069		20020715
EE 200400075	A	20040816	EE 2004-75		20020715
HU 200401620	A2	20041129	HU 2004-1620		20020715
CN 1558897	A	20041229	CN 2002-821635		20020715
JP 2005504778	T2	20050217	JP 2003-523217		20020715
EP 1577305	A1	20050921	EP 2005-104581		20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
AT 323674	E	20060515	AT 2002-745739		20020715
US 2003171377	A1	20030911	US 2002-225716		20020822
ZA 2004000374	A	20050117	ZA 2004-374		20040119
BG 108597	A	20050331	BG 2004-108597		20040224
NO 2004000881	A	20040419	NO 2004-881		20040227
PRIORITY APPLN. INFO.:			US 2001-315728P	P	20010829
			US 2001-322123P	P	20010914
			US 2002-369788P	P	20020403
			EP 2002-745739	A3	20020715
			WO 2002-IB2843	W	20020715

OTHER SOURCE(S): MARPAT 138:221586

AB AXQYC(B)(D)ZE [A = (substituted) (fused) aryl, heteroaryl, cycloalkyl, heterocycloalkyl; X = CH2O, CH2CH2O, (CH2)3, CH2C.tplbond.C, CH2CH:CH; Q = (substituted) (fused) aryl, heteroaryl; Y, Z = null, (CR1R2)n, (CR3R4)m; R1-R4 = H, halo, alkyl, OH, alkoxy; m, n = 1-3; B = H, halo, alkyl, haloalkyl, alkoxy; D = H, (substituted) arylamino, alkanoyl, PhCO, aryl, heteroaryl, cycloalkyl, heterocycloalkyl; E = COR5; R5 = alkyl, OH, alkoxy, amino, sulfonylamino, substituted heteroaryl, dioxothiazolyl, etc.; with provisos], were prepared Thus, (S)-tyrosine Me ester, 2,5-dimethoxytetrahydrofuran, and NaOAc were heated in aqueous HOAc at 100° for 20 min. to give 35% pyrrolotyrosine Me ester. This was stirred with 2-(5-methyl-2-phenyloxazol-4-yl)ethanol, Ph3P, and di-Et azodicarboxylate in THF for 18 h to give 51% Me (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionate. The latter was stirred with LiOH in THF/H2O to give 51% (S)-3-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]-2-pyrrol-1-ylpropionic acid. In a 3T3-L1 adipocyte differentiation assay, title compds. at 5 μM showed 2-183% of the activity of BRL 49653 pos. control. A drug formulation is given.

IT 501027-86-7P 501027-87-8P 501027-94-7P
501027-95-8P 501027-98-1P 501027-99-2P
501028-00-8P 501028-01-9P 501028-02-0P
501028-03-1P 501028-04-2P 501028-05-3P
501028-06-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of azoles as oral antidiabetic agents)

RN 501027-86-7 HCAPLUS

CN 1H-Pyrrole-1-acetic acid, α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501027-87-8 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501027-94-7 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-methyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501027-95-8 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-methyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



RN 501027-98-1 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, 3-bromo-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501027-99-2 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-(trifluoromethyl)-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501028-00-8 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-(trifluoromethyl)-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)-(9CI) (CA INDEX NAME)

Updated Search

Absolute stereochemistry.



RN 501028-01-9 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-ethyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501028-02-0 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-ethyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

RN 501028-03-1 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-propyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501028-04-2 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-propyl-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501028-05-3 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-(fluoromethyl)-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10518679



RN 501028-06-4 HCAPLUS
CN 1H-Pyrrole-1-acetic acid, α-(fluoromethyl)-α-[[4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]methyl]-, (αS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:154382 HCAPLUS
DOCUMENT NUMBER: 138:187795
TITLE: Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors
INVENTOR(S): Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio
PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 1009 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016254	A1	20030227	WO 2002-JP8120	20020808

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

Updated Search

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2457468	AA	20030227	CA 2002-2457468		20020808
EP 1431267	A1	20040623	EP 2002-755874		20020808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK					
BR 2002011810	A	20040824	BR 2002-11810		20020808
CN 1551866	A	20041201	CN 2002-817376		20020808
HU 200401963	A2	20050128	HU 2004-1963		20020808
NZ 531153	A	20051028	NZ 2002-531153		20020808
ZA 2004000973	A	20050104	ZA 2004-973		20040205
NO 2004000564	A	20040510	NO 2004-564		20040206
US 2006258728	A1	20061116	US 2004-486220		20040909
PRIORITY APPLN. INFO.:			JP 2001-241867	A	20010809
			WO 2002-JP8120	W	20020808

OTHER SOURCE(S): MARPAT 138:187795

GI



I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6); A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepared These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid,

Updated Search

phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide , (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)p ropenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propana mide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erythema (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reproduction disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers associated therewith, nerve disorders, vascular dementia, edema, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, reduction of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation containing (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499156-23-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499156-23-9 HCAPLUS

CN Benzenepropanoic acid, 2-[[[1-(3,5-dimethylphenyl)-3-methylbutyl]amino]carbonyl]-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-

yl]methoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:324838 HCAPLUS
DOCUMENT NUMBER: 129:27815
TITLE: Preparation of 2-disubstituted cyclohexenyl and cyclohexyl compounds as antimicrobial agents
INVENTOR(S): Chen, Robert H.; Urbanski, Maud; Xiang, Min; Barrett, John Francis
PATENT ASSIGNEE(S): Ortho Pharmaceutical Corp., USA
SOURCE: U.S., 23 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5753715	A	19980519	US 1995-459447	19950602
ZA 9604511	A	19971201	ZA 1996-4511	19960531
PRIORITY APPLN. INFO.:			US 1995-459447 A	19950602

OTHER SOURCE(S): CASREACT 129:27815; MARPAT 129:27815
GI



I



II

AB The title compds. [I; R1 = (un)branched C1-6 alkyl, C1-6 hydroxyalkyl, etc.; R2 = Ph, heterocyclic moiety, etc.; n = 1-6; q = 0-2; X = NH, O, S] are prepared I are useful antimicrobial agents. Thus, compound (II; W =

OSO2Me) (preparation given) was reacted with 1-(2-aminoethyl)pyrrolidine in EtOH and then treated with oxalic acid to give the title compound II (W = NHCH2CH2Y, Y = 1-pyrrolidyl) as an oxalate salt, which showed inhibition of autophosphorylation of kinase A and the transphosphorylation of ApoOF.

IT 201021-62-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-disubstituted cyclohexenyl and cyclohexyl compds. as antimicrobial agents)

RN 201021-62-7 HCAPLUS
CN Benzenepropanoic acid, 4-[2-[1-(4-fluorophenyl)-2-cyclohexen-1-yl]ethoxy]-, compd. with cyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 201021-61-6
CMF C23 H25 F O3



CM 2

CRN 108-91-8
CMF C6 H13 N



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:28741 HCAPLUS
DOCUMENT NUMBER: 128:88665
TITLE: Preparation of 4-(cyclohexenylethoxy)benzenealkanamines and analogs as bactericides
INVENTOR(S): Chen, Robert H.; Urbanski, Maud; Xiang, Min; Barrett, John F.
PATENT ASSIGNEE(S): Ortho Pharmaceutical Corp., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English

Updated Search

10518679

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748675	A1	19971224	WO 1996-US10357	19960618
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9662801	A1	19980107	AU 1996-62801	19960618
PRIORITY APPLN. INFO.:			WO 1996-US10357 W	19960618
OTHER SOURCE(S):	MARPAT 128:88665			

GI



II

AB R1Z1(CH2)nX(CH2)qR2 [I; R1 = (hydroxy)alkyl, (un)substituted phenyl(alkyl); R2 = substituted Ph or -heterocyclyl; X = O, S, NH; Z1 = e.g., 2-cyclohexen-1-ylidene; n = 1-6; q = 0-2], histidine protein kinase inhibitors, were prepared Thus, 3-ethoxy-2-cyclohexenone was condensed with PhCH2MgCl and the reduced product etherified by PhCH2SOCH:CH2 to give PhCH2ZCH2CH2SOPh which was refluxed in decalin contg, Na2CO3 to give PhCH2Z1CH2CHO (Z1 = 2-cyclohexen-1-ylidene) which was converted in 5 steps to title compound II. Data for biol. activity of I were given.

IT 201021-62-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-(cyclohexenylethoxy)benzenealkanamines and analogs as bactericides)

RN 201021-62-7 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[1-(4-fluorophenyl)-2-cyclohexen-1-yl]ethoxy]-, compd. with cyclohexanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 201021-61-6
CMF C23 H25 F O3



Updated Search

10518679

CM 2

CRN 108-91-8
CMF C6 H13 N



L7 ANSWER 19 OF 19 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:592066 HCAPLUS
DOCUMENT NUMBER: 121:192066
TITLE: the influence of the liquid crystalline core geometry on the mesogenicity of novel chiral 2-(4-substituted-phenoxy)propanonitriles
AUTHOR(S): Booth, Christopher J.; Goodby, John W.; Hardy, Judith P.; Lettington, Olwen C.; Toyne, Kenneth J.
CORPORATE SOURCE: Sch. Chem., Univ. Hull, Hull, HU6 7RX, UK
SOURCE: Liquid Crystals (1994), 16(6), 925-40
CODEN: LICRE6; ISSN: 0267-8292
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The synthesis and characterization of 7 novel (R)-2-(4-substituted-phenoxy)propanonitriles are described. The propanonitriles were prepared to evaluate their potential use as thermochromics and ferroelec. dopants, as well as to determine their twist sense properties. The materials exhibit smectic and chiral nematic phases of high thermal stability; the mesogenic behavior of the nitriles is directly related to the type of 2-ring core unit employed. The effects of the different mol. geometries and polarizabilities of the liquid crystalline cores on mesophase stability are discussed, particularly in relation to other members of this series. The chiral nematic phase of the propanonitriles is assigned as having a left-handed twist sense from contact preparation studies, and this is in agreement with rules absolute configuration and mol. structure to helical twist sense.
IT 157788-48-2P 157788-49-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitrification of)
RN 157788-48-2 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-fluoro-4'-pentyl-, 4-(1-carboxyethoxy)phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10518679



RN 157788-49-3 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-fluoro-4'-pentyl-, 4-(1-carboxyethoxy)phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	112.32	285.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-15.00	-15.00

FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent

Updated Search

assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
=> d his

     (FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1             STRUCTURE UPLOADED
L2               0 S L1
L3             403 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4              20 S L3
L5               0 S L4 AND STEVENAGE, R?/AU
L6               1 S L4 AND BESWICK, P?/AU
L7              19 S L4 NOT L6
L8               0 S L7 AND GOSMINI, R?/AU
L9               0 S L7 AND GRIMES, R?/AU
L10              0 S L7 AND HAMLET, C?/AU
L11              0 S L7 AND HAMLETT, C?/AU
L12              0 S L7 AND KING, N?/AU
L13              0 S L7 AND PATEL, V?/AU
L14              0 S L7 AND BELL, R?/AU

     FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006

=> s l3
L15              0 L3

=>  d his

     (FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1             STRUCTURE UPLOADED
L2               0 S L1
L3             403 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4              20 S L3
L5               0 S L4 AND STEVENAGE, R?/AU
L6               1 S L4 AND BESWICK, P?/AU
L7              19 S L4 NOT L6
L8               0 S L7 AND GOSMINI, R?/AU
L9               0 S L7 AND GRIMES, R?/AU
L10              0 S L7 AND HAMLET, C?/AU
L11              0 S L7 AND HAMLETT, C?/AU
L12              0 S L7 AND KING, N?/AU
L13              0 S L7 AND PATEL, V?/AU
L14              0 S L7 AND BELL, R?/AU
```

Updated Search

10518679

FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006
L15 0 S L3

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	286.07

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-15.00

FILE 'HCAPLUS' ENTERED AT 01:28:08 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 27 Nov 2006 VOL 145 ISS 23
FILE LAST UPDATED: 26 Nov 2006 (20061126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3/thu
20 L3
833110 THU/RL
L16 18 L3/THU
(L3 (L) THU/RL)

=> d l16 not l4
L4 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> d his

(FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1 STRUCTURE UPLOADED
L2 0 S L1
L3 403 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4 20 S L3
L5 0 S L4 AND STEVENAGE, R?/AU

Updated Search

10518679

```
L6            1 S L4 AND BESWICK, P?/AU
L7           19 S L4 NOT L6
L8            0 S L7 AND GOSMINI, R?/AU
L9            0 S L7 AND GRIMES, R?/AU
L10           0 S L7 AND HAMLET, C?/AU
L11           0 S L7 AND HAMLETT, C?/AU
L12           0 S L7 AND KING, N?/AU
L13           0 S L7 AND PATEL, V?/AU
L14           0 S L7 AND BELL, R?/AU

     FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006
L15           0 S L3

     FILE 'HCAPLUS' ENTERED AT 01:28:08 ON 27 NOV 2006
L16          18 S L3/THU

=> s l4 not l16
L17           2 L4 NOT L16

=> d l17, ibib abs hitstr, 1-2

L17  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2004:1019618  HCAPLUS
DOCUMENT NUMBER:          142:69141
TITLE:                    Methods of identifying non-specific inhibitors of
                          biomolecules
INVENTOR(S):              Shoichet, Brian K.; McGovern, Susan L.
PATENT ASSIGNEE(S):       Northwestern University, USA
SOURCE:                   U.S. Pat. Appl. Publ., 16 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     US 2004234942         A1    20041125    US 2002-171814           20020614
     US 6887658            B2    20050503
PRIORITY APPLN. INFO.:                       US 2001-298527P      P   20010615
AB   The invention provides methods of identifying compds. that
     non-specifically inhibit biol. reactions.  The invention further includes
     kits that facilitate this identification.  In addition, compilations of
     compds. for use in high throughput drug screening that have been evaluated
     by the disclosed methodol. are also part of the d invention.  The
     invention provides methods for identifying a false pos. in a screening
     assay by measuring the activity of at least one biol. activity in the
     presence and absence of a small mol. compound capable of inhibiting
     aggregate formation, e.g., digitonin.
IT   813420-84-7
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (methods of identifying non-specific inhibitors of biomols.)
RN   813420-84-7  HCAPLUS
CN   4-Pyridinecarboxylic acid, 2,6-bis(4-chlorophenyl)-, 4-(1-carboxy-3-
     methylbutoxy)phenyl ester (9CI)  (CA INDEX NAME)
```

Updated Search

10518679



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1994:592066 HCAPLUS
DOCUMENT NUMBER: 121:192066
TITLE: the influence of the liquid crystalline core geometry on the mesogenicity of novel chiral 2-(4-substituted-phenoxy)propanonitriles
AUTHOR(S): Booth, Christopher J.; Goodby, John W.; Hardy, Judith P.; Lettington, Olwen C.; Toyne, Kenneth J.
CORPORATE SOURCE: Sch. Chem., Univ. Hull, Hull, HU6 7RX, UK
SOURCE: Liquid Crystals (1994), 16(6), 925-40
CODEN: LICRE6; ISSN: 0267-8292
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthesis and characterization of 7 novel (R)-2-(4-substituted-phenoxy)propanonitriles are described. The propanonitriles were prepared to evaluate their potential use as thermochromics and ferroelec. dopants, as well as to determine their twist sense properties. The materials exhibit smectic and chiral nematic phases of high thermal stability; the mesogenic behavior of the nitriles is directly related to the type of 2-ring core unit employed. The effects of the different mol. geometries and polarizabilities of the liquid crystalline cores on mesophase stability are discussed, particularly in relation to other members of this series. The chiral nematic phase of the propanonitriles is assigned as having a left-handed twist sense from contact preparation studies, and this is in agreement with rules absolute configuration and mol. structure to helical twist sense.

IT 157788-48-2P 157788-49-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and nitrification of)
RN 157788-48-2 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-fluoro-4'-pentyl-, 4-(1-carboxyethoxy)phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

10518679



RN 157788-49-3 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 2'-fluoro-4'-pentyl-, 4-(1-carboxyethoxy)phenyl ester, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.28	301.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-16.50

FILE 'REGISTRY' ENTERED AT 01:29:07 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6
DICTIONARY FILE UPDATES: 24 NOV 2006 HIGHEST RN 913944-64-6

Updated Search

10518679

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\brobinson1\My
Documents\stnweb\Queries\dfdfkl.str

L18   STRUCTURE UPLOADED

=> s l18
SAMPLE SEARCH INITIATED 01:30:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   44386 TO ITERATE

  4.5% PROCESSED   2000 ITERATIONS   0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 875143 TO   900297
PROJECTED ANSWERS: 0 TO   0

L19   0 SEA SSS SAM L18

=> s l18 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 01:30:37 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   888904 TO ITERATE

 98.8% PROCESSED   878521 ITERATIONS   3 ANSWERS

100.0% PROCESSED   888904 ITERATIONS   3 ANSWERS
SEARCH TIME: 00.00.25

L20   3 SEA SSS FUL L18

=> d his

     (FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

     FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006
L1   STRUCTURE UPLOADED
L2   0 S L1
L3   403 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006

Updated Search

10518679

```
L4            20 S L3
L5             0 S L4 AND STEVENAGE, R?/AU
L6             1 S L4 AND BESWICK, P?/AU
L7            19 S L4 NOT L6
L8             0 S L7 AND GOSMINI, R?/AU
L9             0 S L7 AND GRIMES, R?/AU
L10            0 S L7 AND HAMLET, C?/AU
L11            0 S L7 AND HAMLETT, C?/AU
L12            0 S L7 AND KING, N?/AU
L13            0 S L7 AND PATEL, V?/AU
L14            0 S L7 AND BELL, R?/AU

     FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006
L15            0 S L3

     FILE 'HCAPLUS' ENTERED AT 01:28:08 ON 27 NOV 2006
L16           18 S L3/THU
L17            2 S L4 NOT L16

     FILE 'REGISTRY' ENTERED AT 01:29:07 ON 27 NOV 2006
L18              STRUCTURE UPLOADED
L19            0 S L18
L20            3 S L18 FULL

=> s 120 not l3
L21           3 L20 NOT L3

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   167.82     469.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -16.50

FILE 'HCAPLUS' ENTERED AT 01:31:12 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 Nov 2006  VOL 145 ISS 23
FILE LAST UPDATED: 26 Nov 2006  (20061126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.
```

Updated Search

10518679

```
=> s l21
L22          2 L21

=> s l22 and bell, r?/au
          2752 BELL, R?/AU
L23          0 L22 AND BELL, R?/AU

=> s l22 and beswick, p?/au
            57 BESWICK, P?/AU
L24          0 L22 AND BESWICK, P?/AU

=> d l22, ibib abs hitstr, 1-2

L22  ANSWER 1 OF 2  HCAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2005:394829  HCAPLUS
DOCUMENT NUMBER:          142:463605
TITLE:                    Preparation aryloxyacetic acids and related compounds
                          as PPARδ and PPARα agonists
INVENTOR(S):              Ackermann, Jean; Aebi, Johannes; Binggeli, Alfred;
                          Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki,
                          Hans-Peter; Meyer, Markus; Mohr, Peter; Wright,
                          Matthew Blake
PATENT ASSIGNEE(S):       Hoffmann-La Roche Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 89 pp.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE       APPLICATION NO.          DATE
     ---------------      ----   --------   --------------------     --------
     US 2005096337         A1    20050505   US 2004-978155           20041029
     US 7115611            B2    20061003
     AU 2004291262         A1    20050602   AU 2004-291262           20041028
     CA 2543249            AA    20050602   CA 2004-2543249          20041028
     WO 2005049573         A1    20050602   WO 2004-EP12217          20041028
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     EP 1682508            A1    20060726   EP 2004-790987           20041028
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     NO 2006002135         A     20060524   NO 2006-2135             20060512
PRIORITY APPLN. INFO.:                      EP 2003-104081       A   20031105
                                            EP 2004-100759       A   20040226
                                            WO 2004-EP12217      W   20041028
OTHER SOURCE(S):          MARPAT 142:463605
GI
```

Updated Search



I



II

AB Title compds. I [X = O, S, CH2; R1 = H, alkyl; R2 = H, alkyl with provisos; R3 = H, alkyl; R4, R8 = H, alkyl, cycloalkyl, etc.; R5, R6, R7 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, saponification of Et ester II (Z = OEt), afforded acid II (Z = OH) as a light yellow solid. In PPARα receptor binding assays, 3-examples of compds. I exhibited IC50 values ranging from 0.013-0.289 μmmol/l. Compds. I are claimed to be useful for the treatment of diseases modulated by PPARδ and PPARα agonist.

IT 851506-59-7P 851506-60-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation aryloxyacetic acids and related compds. as PPARδ and PPARα agonists)

RN 851506-59-7 HCAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-5-[2-[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)



Updated Search

10518679

RN 851506-60-0 HCAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-5-[[2-methyl-6-[4-(trifluoromethyl)phenyl]-3-pyridinyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:97157 HCAPLUS
DOCUMENT NUMBER: 126:157280
TITLE: Preparation of aromatic alkanoic acid and alkanol derivatives as antithrombotics
INVENTOR(S): Hashizume, Hiroichi; Hagiwara, Masaki; Myamae, Tetsuhisa; Ogawa, Masaji; Ppongo, Tomoko; Morikawa, Tadanori
PATENT ASSIGNEE(S): Fuji Yakuhin Kogyo Kk, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08333287	A2	19961217	JP 1995-158813	19950602
PRIORITY APPLN. INFO.:			JP 1995-158813	19950602

OTHER SOURCE(S): MARPAT 126:157280
GI



I

AB The title compds. I [A = (un)substituted benzene, etc.; X, Y = (O- or N-containing) alkylene; Z = amino, OH, carboxyl, aminocarbonyl, etc.] are prepared The title compds. in vitro showed IC50 values of 0.068 to 15.3 μM against thrombin-induced platelet aggregation.
IT 185995-41-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

Updated Search

10518679

BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic alkanoic acid and alkanol derivs. as antithrombotics)
RN 185995-41-9 HCAPLUS
CN Acetic acid, [3-[2-(4,4''-dimethyl[1,1':2',1''-terphenyl]-4'-yl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



=> file caold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.75	481.92
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.50	-18.00

FILE 'CAOLD' ENTERED AT 01:31:39 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d his

(FILE 'HOME' ENTERED AT 01:16:31 ON 27 NOV 2006)

FILE 'REGISTRY' ENTERED AT 01:16:38 ON 27 NOV 2006

Updated Search

10518679

```
L1              STRUCTURE UPLOADED
L2            0 S L1
L3          403 S L1 FULL

     FILE 'HCAPLUS' ENTERED AT 01:25:22 ON 27 NOV 2006
L4           20 S L3
L5            0 S L4 AND STEVENAGE, R?/AU
L6            1 S L4 AND BESWICK, P?/AU
L7           19 S L4 NOT L6
L8            0 S L7 AND GOSMINI, R?/AU
L9            0 S L7 AND GRIMES, R?/AU
L10           0 S L7 AND HAMLET, C?/AU
L11           0 S L7 AND HAMLETT, C?/AU
L12           0 S L7 AND KING, N?/AU
L13           0 S L7 AND PATEL, V?/AU
L14           0 S L7 AND BELL, R?/AU

     FILE 'CAOLD' ENTERED AT 01:27:56 ON 27 NOV 2006
L15           0 S L3

     FILE 'HCAPLUS' ENTERED AT 01:28:08 ON 27 NOV 2006
L16          18 S L3/THU
L17           2 S L4 NOT L16

     FILE 'REGISTRY' ENTERED AT 01:29:07 ON 27 NOV 2006
L18             STRUCTURE UPLOADED
L19           0 S L18
L20           3 S L18 FULL
L21           3 S L20 NOT L3

     FILE 'HCAPLUS' ENTERED AT 01:31:12 ON 27 NOV 2006
L22           2 S L21
L23           0 S L22 AND BELL, R?/AU
L24           0 S L22 AND BESWICK, P?/AU

     FILE 'CAOLD' ENTERED AT 01:31:39 ON 27 NOV 2006

=> s l21
L25           0 L21

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.44     482.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00     -18.00

FILE 'REGISTRY' ENTERED AT 01:31:47 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   24 NOV 2006  HIGHEST RN 913944-64-6
DICTIONARY FILE UPDATES:  24 NOV 2006  HIGHEST RN 913944-64-6
```

Updated Search

10518679

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Documents and Settings\brobinson1\My Documents\stnweb\Queries\aqkm.str

L26 STRUCTURE UPLOADED

=> s l26
SAMPLE SEARCH INITIATED 01:32:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 44386 TO ITERATE

4.5% PROCESSED 2000 ITERATIONS 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 875143 TO 900297
PROJECTED ANSWERS: 0 TO 0

L27 0 SEA SSS SAM L26

=> s l26 full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 166.50 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 01:33:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 888904 TO ITERATE

98.8% PROCESSED 878614 ITERATIONS 0 ANSWERS

100.0% PROCESSED 888904 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.25

L28 0 SEA SSS FUL L26

=>

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	167.82	650.18

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-18.00

Updated Search

10518679

FILE 'HCAPLUS' ENTERED AT 01:33:34 ON 27 NOV 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 27 Nov 2006 VOL 145 ISS 23
FILE LAST UPDATED: 26 Nov 2006 (20061126/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s bell, r?/au and beswich, p?/au and gosmini, r?/au and grimes, r?/au and
hamlett, c?/au and king, n?/au and patel, v?/au
2752 BELL, R?/AU
0 BESWICH, P?/AU
17 GOSMINI, R?/AU
570 GRIMES, R?/AU
2 HAMLETT, C?/AU
596 KING, N?/AU
1127 PATEL, V?/AU
L29 0 BELL, R?/AU AND BESWICH, P?/AU AND GOSMINI, R?/AU AND GRIMES,
R?/AU AND HAMLETT, C?/AU AND KING, N?/AU AND PATEL, V?/AU

=> s bell, r?/au and beswick, p?/au and gosmini, r?/au and hamlett, c?/au and king,
n?/au and patel, v?/au
2752 BELL, R?/AU
57 BESWICK, P?/AU
17 GOSMINI, R?/AU
2 HAMLETT, C?/AU
596 KING, N?/AU
1127 PATEL, V?/AU
L30 1 BELL, R?/AU AND BESWICK, P?/AU AND GOSMINI, R?/AU AND HAMLETT,
C?/AU AND KING, N?/AU AND PATEL, V?/AU

=> d l30, ibib abs hitstr, 1

L30 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:2698 HCAPLUS
DOCUMENT NUMBER: 140:59519
TITLE: Preparation of (biphenylylalkoxy)- and
[(phenylpyridyl)alkoxy]-substituted phenylalkanoic
acids and phenoxyalkanoic acids as hPPAR activators
for treatment of cardiovascular disease and related
disorders
INVENTOR(S): Hamlett, Christopher Charles Frederick;
Bell, Richard; Beswick, Paul John;

Updated Search

10518679

	Gosmini, Romain Luc Marie; King, Nigel Paul; Patel, Vipulkumar Kantibhai
PATENT ASSIGNEE(S):	Smithkline Beecham Corporation, USA
SOURCE:	PCT Int. Appl., 158 pp.
	CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000315	A1	20031231	WO 2003-EP6415	20030618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2487909	AA	20031231	CA 2003-2487909	20030618
AU 2003245962	A1	20040106	AU 2003-245962	20030618
EP 1513526	A1	20050316	EP 2003-738056	20030618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011931	A	20050405	BR 2003-11931	20030618
CN 1674897	A	20050928	CN 2003-819290	20030618
JP 2005534672	T2	20051117	JP 2004-514761	20030618
NZ 537210	A	20060929	NZ 2003-537210	20030618
NO 2004005328	A	20050309	NO 2004-5328	20041203
US 2006089394	A1	20060427	US 2005-518679	20050816
PRIORITY APPLN. INFO.:			GB 2002-14149 A	20020619
			WO 2003-EP6415 W	20030618

OTHER SOURCE(S): MARPAT 140:59519

GI



I



II

Updated Search

10518679

AB Title compds. I [wherein R1 and R2 = independently H or alkyl; X = O or (CH2)n; n = 0-2; R3 R4 = independently H, alkyl, OMe, CF3, allyl, or halo; X1 = O, S, SO2, SO, or CH2; R5 and R6 = independently H, (halo)alkyl, or alkoxyalkyl; or CR5R6 = cycloalkyl; R7 = (un)substituted Ph or 6-membered heteroaryl; and pharmaceutically acceptable salts, solvates, and hydrolyzable esters thereof] were prepared as human peroxisome proliferator activated receptor (hPPAR) activators. For example, a mixture of 3-(bromomethyl)-4'-(trifluoromethyl)biphenyl, Et (4-mercapto-2-methylphenoxy)acetate, and polymer-supported diisopropylethylamine in DCM was stirred at room temperature overnight to give the thioether. Saponification of the ester with aqueous NaOH in THF and acidification afforded II. Compds. of the invention showed at least 50% activation of hPPARδ relative to the pos. control at concns. of 10-7 M or less. Thus, I and their pharmaceutical compns. are useful for the treatment of hPPAR mediated conditions, such as dyslipidemia, syndrome X, heart failure, hypercholesterolemia, cardiovascular disease, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, obesity, anorexia bulimia, or anorexia nervosa (no data).

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Updated Search